Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof

ABSTRACT

Adenovirus vectors replication specific for cells expressing α-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.09/593,308, filed Jun. 13, 2000, now abandoned, which is a continuationof U.S. patent application Ser. No. 09/033,428, filed Mar. 2, 1998, nowU.S. Pat. No. 6,254,862, which claims the benefit of U.S. ProvisionalApplication Serial No. 60/039,597, filed Mar. 3, 1997, all of which areincorporated by reference herein in their entirety.

TECHNICAL FIELD

This invention relates to cell transfection using adenoviral vectors.More specifically, it relates to cell-specific replication of adenovirusvectors in cells expressing alpha-fetoprotein, particularly hepatomacells.

BACKGROUND OF THE INVENTION

In spite of extensive medical research and numerous advances, cancerremains the second leading cause of death in the United States.Hepatocellular carcinoma (HCC or malignant hepatoma) is one of the mostcommon cancers in the world, and is especially problematic in Asia.

Treatment prospects for patients with hepatocellular carcinoma are dim.Even with improvements in therapy and availability of liver transplant,only a minority of patients are cured by removal of the tumor either byresection or transplantation. For the majority of patients, the currenttreatments remain unsatisfactory, and the prognosis is poor.

Of particular interest is development of more specific, targeted formsof cancer therapy, especially in cancers that are difficult to treatsuccessfully, such as hepatoma. In contrast to conventional cancertherapies, which result in relatively non-specific and often serioustoxicity, more specific treatment modalities attempt to inhibit or killmalignant cells selectively while leaving healthy cells intact.

One possible treatment approach for cancers such as hepatoma is genetherapy, whereby a gene of interest is introduced into the malignantcell. The gene of interest may encode a protein which converts into atoxic substance upon treatment with another compound, or an enzyme thatconverts a prodrug to a drug. For example, introduction of the herpessimplex gene encoding thymidine kinase (HSV-tk) renders cellsconditionally sensitive to ganciclovir (GCV). Alternatively, the gene ofinterest may encode a compound that is directly toxic, such asdiphtheria toxin (DT). For these treatments to be rendered specific tocancer cells, the gene of interest can be under control of atranscriptional initiation region that is specifically (i.e.,preferentially) activated in the cancer cells. Cell or tissue specificexpression can be achieved by using cell-specific enhancers and/orpromoters. See generally Huber et al. (1995) Adv. Drug Delivery Reviews17:279-292.

A variety of viral and non-viral (e.g., liposomes) vehicles, or vectors,have been developed to transfer these genes. Of the viruses,retroviruses, herpes simplex virus, adeno-associated virus, Sindbisvirus, poxvirus, and adenoviruses have been proposed for gene transferwith retrovirus vectors or adenovirus vectors being the focus of muchcurrent research. Adenoviruses are among the most easily produced andpurified, whereas retroviruses are unstable, difficult to produce and topurify, and may integrate into the host genome, raising the possibilityof dangerous mutations. Moreover, adenovirus has the advantage ofeffecting high efficiency of transduction and does not require cellproliferation for efficient transduction of cell. For general backgroundreferences regarding adenovirus and development of adenoviral vectorsystems, see Graham et al. (1973) Virology 52:456-467; Takiff et al.(1981) Lancet 11:832-834; Berkner et al. (1983) Nucleic Acid Research11: 6003-6020; Graham (1984) EMBO J 3:2917-2922; Bett et al. (1993) J.Virology 67:5911-5921; and Bett et al. (1994) Proc. Natl. Acad. Sci. USA91:8802-8806.

When used as gene transfer vehicles, adenovirus vectors are oftendesigned to be replication-defective and are thus deliberatelyengineered to fail to replicate in the target cells of interest. Inthese vehicles, the early adenovirus gene products E1A and/or E1B aredeleted and provided in trans by the packaging cell line 293. Graham etal. (1987) J. Gen. Virol 36:59-72; Graham (1977) J. Genetic Virology68:937-940. The gene to be transduced is commonly inserted intoadenovirus in the E1A and E1B region of the virus genome. Bett et al.(1994). Replication-defective adenovirus vectors as vehicles forefficient transduction of genes have been described by, inter alia,Stratford-Perricaudet (1990) Human Gene Therapy 1:241-256; Rosenfeld(1991) Science 252:431-434; Wang et al. (1991) Adv. Exp. Med Biol.309:61-66; Jaffe et al. (1992) Nat. Gen. 1:372-378; Quantin et al.(1992) Proc. Natl. Acad. Sci. USA 89:2581-2584; Rosenfeld et al. (1992)Cell 68:143-155; Stratford-Perricaudet et al. (1992) J. Clin. Invest.90:626-630; Le Gal Le Salle et al. (1993) Science 259:988-990Mastrangeli et al. (1993) J. Clin. Invest. 91:225-234; Ragot et al.(1993) Nature 361:647-650; Hayaski et al. (1994) J. Biol. Chem.269:23872-23875; Bett et al. (1994).

The virtually exclusive focus in development of adenoviral vectors forgene therapy is use of adenovirus merely as a vehicle for introducingthe gene of interest, not as an effector in itself. Replication ofadenovirus has been viewed as an undesirable result, largely due to thehost immune response. In the treatment of cancer byreplication-defective adenoviruses, the host immune response limits theduration of repeat doses at two levels. First, the capsid proteins ofthe adenovirus delivery vehicle itself are immunogenic. Second, virallate genes are frequently expressed in transduced cells, elicitingcellular immunity. Thus, the ability to repeatedly administer cytokines,tumor suppressor genes, ribozymes, suicide genes, or genes which convertprodrug to an active drug has been limited by the immunogenicity of boththe gene transfer vehicle and the viral gene products of the transfervehicle as well as the transient nature of gene expression. There is aneed for vector constructs that are capable of eliminating essentiallyall cancerous cells in a minimum number of administrations beforespecific immunological response against the vector prevents furthertreatment.

A completely separate area of research pertains to the description oftissue-specific regulatory proteins. α-Fetoprotein (AFP) is an oncofetalprotein, the expression of which is primarily restricted to developingtissues of endodermal origin (yolk sac, fetal liver, and gut), althoughthe level of its expression varies greatly depending on the tissue andthe developmental stage. AFP is of clinical interest because the serumconcentration of AFP is elevated in a majority of hepatoma patients,with high levels of AFP found in patients with advanced disease. Theserum AFP levels in patients appear to be regulated by AFP expression inhepatocellular carcinoma but not in surrounding normal liver. Thus, theAFP gene appears to be regulated to hepatoma cell-specific expression.

The 5′ upstream flanking sequence of the human AFP gene has been shownto confer cell-specific enhancer activity. Watanabe et al. (1987) J.Biol. Chem. 262:4812-4818; see also Sakai et al. (1985) J. Biol. Chem.260:5055-5060 (describing cloning the human AFP gene). Canadian pat.appl. no. 2,134,994. An enhancer is a cis-acting transcriptionalregulatory element known to play a major role in determination ofcell-specificity of gene expression. The enhancer is also typicallycharacterized by its ability to augment transcription over a longdistance and relatively independently of orientation and position withrespect to its respective gene. A promoter is located immediately 5′(upstream) of the transcription start site and generally includes anAT-rich region called a TATA box.

Several approaches for gene therapy using the cell-specific AFP enhancerto treat hepatoma have been described. Tamaoki and Nakabayashi describeusing the AFP transcriptional regulatory regions to drive expression inAFP-producing cells, particularly linking a gene encoding a cancer celltoxin to the AFP transcriptional regulatory region. Canadian pat. app.no. 2,134,994. However, the entire focus of this publication was that ofexpression of a heterologous toxin gene, such as the gene encodingdiphtheria toxin (DT), and adenovirus was only described in terms of adelivery vehicle for this toxin gene. Kaneko et al. and Kanai et al.describe adenovirus-mediated gene therapy of hepatoma using the 5′upstream region of AFP to restrict HSV-tk gene expression tohepatocellular carcinoma cells, followed by treatment with nucleosideanalog GCV. Cancer Res. 55:5283-5287 (1995); Hepatology 22 (4 Part 2):Abstract 158A (1995); Hepatology 23:1359-1368 (1996); Hepatology22:Abstract 328 (1995). However, these adenovirus constructs arereplication defective, and the entire focus of these publications isusing the AFP 5′ upstream transcriptional regulatory region to controlexpression of a non-adenovirus gene. Wills et al.(1995) also describereplication-deficient adenoviral vectors which selectively expressHSV-tk. Cancer Gene Ther. 2:191-197. Kanai et al. (1996) also reportedusing the AFP enhancer-promoter to drive expression of the lacZ gene andthe E. coli cytosine deaminase (CD) gene in addition to the HSV-tk gene.Gastroenterology (Supp) 110:A1227. Again, the focus and approachentailed using replication-deficient adenovirus as a therapeutic genedelivery vehicle, not as an agent per se for effecting selective growthinhibition. See also Arbuthnot et al. (1996) (describing using 5′flanking sequences from rat AFP gene). Human Gene Ther. 7:1503-1514.

Hepatocellular carcinoma is rarely curable by standard therapies. Thus,it is critical to develop new therapeutic approaches for this disease.The present invention addresses this need by providing adenoviralvectors specific for replication in AFP-producing cells.

All publications cited herein are hereby incorporated by reference intheir entirety.

SUMMARY OF THE INVENTION

Replication-competent adenoviral vectors specific, inter alia, for cellsexpressing AFP and methods for their use are provided. In preferredembodiments, these replication competent-adenovirus vectors comprise oneor more of the early and/or late genes essential for adenoviralpropagation is under transcriptional control of an AFP transcriptionalregulatory element (TRE). A transgene under control of the AFP-TREcell-specific promoter may also be present. The invention also providesnon-naturally-occurring adenoviral vectors comprising the codingsequence for adenovirus death protein (ADP) polypeptide, which may ormay not be under cell-specific transcriptional control.

Accordingly, in one aspect, the invention provides an adenovirus vectorcomprising an adenovirus gene, preferably an adenovirus gene essentialfor replication, wherein said adenovirus gene is under transcriptionalcontrol of an α-fetoprotein transcription response element (AFP-TRE). Inone embodiment, an AFP-TRE is human. In one embodiment, an AFP-TREcomprises an AFP-specific promoter and enhancer (i.e., promoter andenhancer from an AFP gene).

In some embodiments, the adenovirus gene essential for replication is anearly gene. In another embodiment, the early gene is E1A. In anotherembodiment, the early gene is E1B. In yet another embodiment, both E1Aand E1B are under transcriptional control of an AFP-TRE. In yet anotherembodiment, E1A, E1B, and E4 are under control of AFP-TREs.

In other embodiments, the adenovirus gene essential for replication is alate gene.

In another embodiment, the AFP-TRE comprises enhancer element A. Inanother embodiment, the AFP-TRE comprises enhancer element B. In anotherembodiment, the AFP-TRE comprises enhancer elements A and B.

In another embodiment, the AFP-TRE comprises the nucleotide sequence ofSEQ ID NO: 1 or a functionally preserved variant thereof. In anotherembodiment, the AFP-TRE comprises a nucleotide sequence from about +1 toabout +600 of SEQ ID NO: 1. In another embodiment, the AFP-TRE comprisesa nucleotide sequence from about +600 to about +827 of SEQ ID NO: 1. Inanother embodiment, the AFP-TRE comprises a nucleotide sequence fromabout +1 to about +300 of SEQ ID NO: 1.

In another embodiment, the AFP-TRE comprises the nucleotide sequence ofSEQ ID NO: 2 or a functionally preserved variant thereof.

In other embodiments, the adenovirus vector can further comprise atransgene, wherein said transgene is under transcriptional control of anAFP-TRE. In some embodiments, the transgene is a cytotoxic gene.

In other embodiments, the adenovirus vector can further comprise anotheradenovirus gene, such as an adenovirus gene necessary for replication,under transcriptional control of an AFP-TRE. In other embodiments, yetan another additional adenovirus gene can be under transcriptionalcontrol of a third AFP-TRE.

In another aspect, the invention provides a host cell comprising theadenovirus vector(s) described herein.

In another aspect, the invention provides compositions comprising anadenovirus vector(s) described herein, especially an effective amount ofan adenovirus vector(s) described herein. The compositions describedherein may also further comprise a pharmaceutically acceptableexcipient.

In another aspect, the invention provides kits which contain anadenoviral vector(s) described herein.

Another embodiment of the invention is an adenovirus which replicatespreferentially in cells which allow an AFP-TRE to function, especiallymammalian cells expressing AFP or capable of expressing AFP.

In another aspect, methods are provided for propagating an adenovirusspecific for cells which allow an AFP-TRE to function, such as cells(particularly mammalian cells) expressing AFP, said method comprisingcombining an adenovirus vector(s) described herein with cells whichallow an AFP-TRE to function, whereby said adenovirus is propagated.

In another aspect, methods are provided for conferring selectivecytotoxicity in cells which allow an AFP-TRE to function, such as cellsexpressing AFP, comprising contacting the AFP-expressing cells with anadenovirus vector(s) described herein, wherein the adenovirus vectorenters the cell.

In another aspect, methods are provided for detecting cells which allowan AFP-TRE to function, comprising contacting cells of a biologicalsample with an adenovirus vector(s) described herein and detectingAFP-TRE mediated expression, if any.

In another aspect, methods are provided for detecting cells expressingα-fetoprotein in a biological sample, comprising contacting cells of abiological sample with an adenovirus vector(s) described herein, anddetecting replication of the adenovirus vector, if any.

In another aspect, methods of treatment are provided wherein anadenoviral vector(s) described herein is administered to an individual.

In another aspect, the invention provides a non-naturally occurringadenoviral vector comprising a polynucleotide encoding adenovirus deathprotein (ADP) polypeptide. In some embodiments, the ADP coding sequenceis under transcriptional control of a cell-specific TRE, such as anAFP-TRE or a prostate-cell specific TRE.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A depicts a schematic map of the human AFP enhancer and promoterregion (not to scale). FIG. 1A shows some of the features of thepromoter/enhancer region, including: enhancer domains A and B; distalsilencer (Sd); proximal silencer (Sp); and glucocorticoid responseelement (GRE). Numbers indicate nucleotide positions relative to thetranscription start site (indicated by bent arrow). FIG. 1B is aschematic depicting two 5′ AFP regions used in constructing an AFP-TRE(described in Example 1).

FIGS. 2(A) and (B) summarize a reporter assay experiment for an AFP-TRE.FIG. 2(A) is a schematic of CN236, a luciferase reporter plasmidconstruct that was used to assess transcriptional activity of anAFP-TRE. FIG. 2(B) is a bar graph depicting a luciferase reporter assayfor an 800 bp AFT-TRE. The 800 bp fragment was tested for its ability todrive expression of luciferase in Hep3B cells which produce AFP.pGL2-Luc is a negative control in which the luciferase gene is notlinked to AFP-TRE sequences.

FIG. 3 is a schematic depicting various adenoviral vector construct asdescribed in Example 1.

FIG. 4 is a schematic depiction of an adenoviral vector in which E1A andE1B are under control of an AFP-TRE, with E1A and E1B in oppositeorientations.

FIGS. 5A and B are schematic depictions an adenovirus death protein(ADP) cassette for insertion into Ad. Arrows underneath FIG. 5A indicatepositions of primers. FIG. 5B depicts the annealed fragment containingthe Y leader sequence and the ADP coding sequence.

FIGS. 6(A), (B) and (C) are half tone reproductions depicting westernanalysis of E1A levels in CN733 (containing two AFP-TREs) and CN702(control) infected cells. In FIG. 6(A), the left panel shows Huh-7(AFP+) cells; the right panel shows Dld-1 (AFP−) cells. In FIG. 6(B),Sk-Hep-1 were the AFP−cells used.

FIGS. 7(A)-(C) are graphs depicting growth of CN733 in AFP producing(Huh-7; FIG. 7(A)) and non-AFP producing (Sk-Hep-1, FIG. 7(B); Dld-1,FIG. 7(C)) cells.

FIGS. 8(A)-(C) are graphs depicting growth of CN732 (FIG. 8(A); soliddiamonds), CN733 (FIG. 8(B); solid diamonds), and CN734 (FIG. 8(C);solid diamonds) in HepG2 cells, as compared to control CN702 (solidsquares).

FIGS. 9(A)-(C) are graphs depicting growth of CN732 (FIG. 9(A); solidsquares), CN733 (FIG. 9(B); solid circles), and CN734 (FIG. 9(C); solidcircles) in primary hepatocytes, compared to control CN702 (soliddiamonds).

FIGS. 10(A)-(B) are graphs comparing tumor volume in mice harboringhepatocarcinoma cell line HepG2 and treated with CN733 (FIG. 9(A);squares) or with control buffer (circles). FIG. 10(A) depicts measuringtumor volume over a period of 43 days (six weeks). In FIG. 10(B), singleintratumoral administration of CN733 (“B”) was compared to fiveconsecutive daily doses of CN733 (“J”).

FIG. 11 is a graph depicting serum AFP levels in tumor-bearing micereceiving CN733 (triangles) or receiving buffer (circles).

FIG. 12 is a graph depicting cytotoxicity of an adenoviral vectorcontaining the coding sequence for adenoviral death protein (ADP), CN751(solid squares), compared to control CN702 (solid circles), Rec 700(solid triangles) and mock infection (Xs).

FIG. 13 is a graph comparing extracellular virus yield of CN751 (solidsquares) and CN702 (solid circles).

FIG. 14 is a graph comparing tumor volume in mice harboring LNCaP tumorxenografts challenged with CN751 (“H”), CN702 (“J”), or buffer (“B”).

MODES FOR CARRYING OUT THE INVENTION

We have discovered and constructed replication competent-adenovirusvectors which can preferentially replicate in cells that expressα-fetoprotein (AFP) and developed methods using these adenovirusvectors. The adenovirus vectors of this invention comprise at least oneadenovirus gene, preferably an adenovirus gene that contributes tocytotoxicity, preferably an adenovirus gene necessary for adenoviralreplication, preferably at least one early gene, under thetranscriptional control of a transcriptional response element (TRE)specifically regulated by binding of transcriptional factor(s) and/orco-factor(s) necessary for transcription of the AFP gene (AFP-TRE). Byproviding for cell-specific transcription of at least one. adenovirusgene required for replication, the invention provides adenovirus vectorsthat can be used for specific cytotoxic effects due to selectivereplication. This is especially useful in the cancer context, in whichtargeted cell killing is desirable. The vectors can also be useful fordetecting the presence of AFP-producing cells in, for example, anappropriate biological (such as clinical) sample. Further, theadenovirus vector(s) can optionally selectively produce one or moreproteins of interest in a target cell by using an AFP-TRE.

We have found that adenovirus vectors of the invention replicatepreferentially in AFP-producing cells (i.e., at a significantly higheryield than in non-AFP producing cells). This replication preference isindicated by comparing the level of replication (i.e., titer) in cellsproducing AFP to the level of replication in cells not producing AFP.The replication preference is even more significant, as the adenovirusvectors of the invention actually replicate at a significantly lowerrate in non-AFP producing cells than wild type virus. Comparison of thetiter of an AFP+ cell type to the titer of an AFP− cell type provides akey indication that the overall replication preference is enhanced dueto depressed replication in AFP− cells as well as the replication inAFP+ cells when compared to wild type adenovirus. This aspect isparticularly significant and useful in the cancer context, in which itis desirable to minimize cytotoxic damage to non-target (i.e.,non-cancerous cells). Example 1 provides a more detailed description ofthese experiments and findings.

Further, we have found that an adenovirus vector of the inventionsignificantly retarded growth of a HepG2 xenograft in nude mice (Example5). Thus, the invention uses and takes advantage of what has beenconsidered an undesirable aspect of adenoviral vectors, namely, theirreplication and possibly concomitant immunogenicity. The probability ofrunaway infection is significantly reduced due to the cell-specificrequirements for viral replication. Without wishing to be bound by anyparticular theory, the inventors note that production of adenovirusproteins can serve to activate and/or stimulate the immune system,generally and/or specifically toward target cells producing adenoviralproteins, which can be an important consideration in the cancer context,where patients are often moderately to severely immunocompromised.

We have also discovered that inclusion of a coding sequence for ADPsignificantly enhances the extent of cytotoxicity, cell killing, andvirus production when compared to an adenoviral vector lacking thissequence. Accordingly, non-naturally occurring adenovirus vectorscontaining a coding sequence for an ADP polypeptide are included anddescribed herein. The ADP coding sequence may or may not be undertranscriptional control of a cell-specific TRE (i.e., under selectivetranscriptional control), such as an AFP-TRE.

General Techniques

The practice of the present invention will employ, unless otherwiseindicated, conventional techniques of molecular biology (includingrecombinant techniques), microbiology, cell biology, biochemistry, andimmunology, which are within the skill of the art. Such techniques areexplained fully in the literature, such as, “Molecular Cloning: ALaboratory Manual”, second edition (Sanbrook et al., 1989);“Oligonucleotide Synthesis” (M. J. Gait, ed., 1984); “Animal CellCulture” (R. I. Freshney, ed., 1987); “Methods in Enzymology” (AcademicPress, Inc.); “Handbook of Experimental Immunology” (D. M. Wei & C. C.Blackwell, eds.); “Gene Transfer Vectors for Mammalian Cells” (J. M.Miller & M. P. Calos, eds., 1987); “Current Protocols in MolecularBiology” (F. M. Ausubel et al., eds., 1987); “PCR: The Polymerase ChainReaction”, (Mullis et al., eds., 1994); “Current Protocols inImmunology” (J. E. Coligan et al., eds., 1991).

For techniques related to adenovirus, see, inter alia, Felgner andRingold (1989) Nature 337:387-388; Berkner and Sharp (1983) Nucl. AcidsRes. 11:6003-6020; Graham (1984) EMBO J. 3:2917-2922; Bett et al. (1993)J. Virology 67:5911-5921; Bett et al. (1994) Proc. Natl. Acad. Sci. USA91:8802-8806.

Definitions

As used herein, an “α-fetoprotein transcriptional response element”, or“AFP-TRE” is polynucleotide sequence, preferably a DNA sequence, whichincreases transcription of an operably linked polynucleotide sequence ina host cell that allows an AFP-TRE to function, such as a host cell thatexpresses AFP. According to published reports, the AFP-TRE is responsiveto cellular proteins (transcription factors and/or co-factor(s))associated with APP-producing cells, such as AFP-binding protein (see,for example, U.S. Pat. No. 5,302,698) and comprises at least a portionof an AFP promoter and/or an AFP enhancer. Methods are described hereinfor measuring the activity of an AFP-TRE and thus for determiningwhether a given cell allows an AFP-TRE to function.

As described in more detail herein, an AFP-TRE can comprise any numberof configurations, including, but not limited to, an AFP promoter; anAFP enhancer; an AFP promoter and an AFP enhancer; an AFP promoter and aheterologous enhancer; a heterologous promoter and an AFP enhancer; andmultimers of the foregoing. The promoter and enhancer components of anAFP-TRE may be in any orientation and/or distance from the codingsequence of interest, as long as the desired AFP cell-specifictranscriptional activity is obtained. Transcriptional activation can bemeasured in a number of ways known in the art (and described in moredetail below), but is generally measured by detection and/orquantitation of mRNA or the protein product of the coding sequence undercontrol of (i.e., operably linked to)-the AFP-TRE. As discussed herein,an AFP-TRE can be of varying lengths, and of varying sequencecomposition. By “transcriptional activation” or an “increase intranscription,” it is intended that transcription is increased abovebasal levels in the target cell (i.e., AFP-producing cell) by at leastabout 2 fold, preferably at least about 5 fold, preferably at leastabout 10 fold, more preferably at least about 20 fold, more preferablyat least about 50 fold, more preferably at least about 100 fold, morepreferably at least about 200 fold, even more preferably at least about400 fold to about 500 fold, even more preferably at least about 1000fold. Basal levels are generally the level of activity (if any) in anon-AFP producing cell, or the level of activity (if any) of a reporterconstruct lacking an AFP-TRE as tested in an AFP-producing cell.Optionally, a transcriptional terminator or transcriptional “silencer”can be placed upstream of the AFP-TRE, thus preventing unwantedread-through transcription of the coding segment under transcriptionalcontrol of the PB-TRE. Also, optionally, the endogenous promoter of thecoding segment to be placed under transcriptional control of the PB-TREcan be deleted.

A “functionally-preserved” variant of an AFP-TRE is an AFP-TRE whichdiffers from another AFP-TRE, but still retains ability to increasetranscription of an operably linked polynucleotide, especially AFPcell-specific transcription activity. The difference in an AFP-TRE canbe due to differences in linear sequence, arising from, for example,single or multiple base mutation(s), addition(s), deletion(s), and/ormodification(s) of the bases. The difference can also arise from changesin the sugar(s), and/or linkage(s) between the bases of an AFP-TRE.

A “cell-specific TRE” is preferentially functional in a specific type ofcell relative to other types of cells of different functionality. Acell-specific TRE may or may not be tumor cell specific.

As used herein, the term “target cell-specific” is intended to mean thatthe TRE sequences to which a gene essential for replication of anadenoviral vector is operably linked, or to which a transgene isoperably linked, functions specifically in that target cell so thatreplication proceeds in that target cell, or so that a transgenepolynucleotide is expressed in that target cell. This can occur byvirtue of the presence in that target cell, and not in non-target cells,of transcription factors that activate transcription driven by theoperably linked transcriptional control sequences. It can also occur byvirtue of the absence of transcription inhibiting factors that normallyoccur in non-target cells and prevent transcription driven by theoperably linked transcriptional control sequences. The term “targetcell-specific”, as used herein, is intended to include cell typespecificity, tissue specificity, as well as specificity for a cancerousstate of a given target cell. In the latter case, specificity for acancerous state of a normal cell is in comparison to a normal,non-cancerous counterpart.

An “adenovirus vector” or “adenoviral vector” (used interchangeably) isa term well understood in the art and generally comprises apolynucleotide comprising all or a portion of an adenovirus genome. Forpurposes of the present invention, an adenovirus vector contains anAFP-TRE operably linked to a polynucleotide. The operably linkedpolynucleotide can be an adenovirus gene or a heterologous gene. Anadenoviral vector construct of this invention may be in any ofseveral-forms, including, but not limited to, naked DNA, DNAencapsulated in an adenovirus coat, DNA packaged in another viral orviral-like form (such as herpes simplex, and AAV), encapsulated inliposomes, complexed with polylysine, complexed with syntheticpolycationic molecules, conjugated with transferrin, and complexed withcompounds such as PEG to immunologically “mask” the molecule and/orincrease half-life, and conjugated to a nonviral protein. Preferably,the polynucleotide is DNA. As used herein, “DNA” includes not only basesA, T, C, and G, but also includes any of their analogs or modified formsof these bases, such as methylated nucleotides, internucleotidemodifications such as uncharged linkages and thioates, use of sugaranalogs, and modified and/or alternative backbone structures, such aspolyamides. For purposes of this invention, adenovirus vectors arereplication-competent in a target cell.

The terms “polynucleotide” and “nucleic acid”, used interchangeablyherein, refer to a polymeric form of nucleotides of any length, eitherribonucleotides or deoxyribonucleotides. These terms include a single-,double- or triple-stranded DNA, genomic DNA, cDNA, RNA, DNA-RNA hybrid,or a polymer comprising purine and pyrimidine bases, or other natural,chemically, biochemically modified, non-natural or derivatizednucleotide bases. The backbone of the polynucleotide can comprise sugarsand phosphate groups (as may typically be found in RNA or DNA), ormodified or substituted sugar or phosphate groups. Alternatively, thebackbone of the polynucleotide can comprise a polymer of syntheticsubunits such as phosphoramidates and thus can be a oligodeoxynucleosidephosphoramidate (P-NH2) or a mixed phosphoramidate-phosphodiesteroligomer. Peyrottes et al. (1996) Nucleic Acids Res. 24: 1841-8;Chaturvedi et al. (1996) Nucleic Acids Res. 24: 2318-23; Schultz et al.(1996) Nucleic Acids Res. 24: 2966-73. A phosphorothiate linkage can beused in place of a phosphodiester linkage. Braun et al. (1988) J.Immunol. 141: 2084-9; Latimer et al. (1995) Mol. Immunol. 32: 1057-1064.In addition, a double-stranded polynucleotide can be obtained from thesingle stranded polynucleotide product of chemical synthesis either bysynthesizing the complementary strand and annealing the strands underappropriate conditions, or by synthesizing the complementary strand denovo using a DNA polymerase with an appropriate primer.

The following are non-limiting examples of polynucleotides: a gene orgene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA,recombinant polynucleotides, branched polynucleotides, plasmids,vectors, isolated DNA of any sequence, isolated RNA of any sequence,nucleic acid probes, and primers. A polynucleotide may comprise modifiednucleotides, such as methylated nucleotides and nucleotide analogs,uracyl, other sugars and linking groups such as fluororibose andthioate, and nucleotide branches. The sequence of nucleotides may beinterrupted by non-nucleotide components. A polynucleotide may befurther modified after polymerization, such as by conjugation with alabeling component. Other types of modifications included in thisdefinition are caps, substitution of one or more of the naturallyoccurring nucleotides with an analog, and introduction of means forattaching the polynucleotide to proteins, metal ions, labelingcomponents, other polynucleotides, or a solid support. Preferably, thepolynucleotide is DNA. As used herein, “DNA” includes not only bases A,T, C, and G, but also includes any of their analogs or modified forms ofthese bases, such as methylated nucleotides, internucleotidemodifications such as uncharged linkages and thioates, use of sugaranalogs, and modified and/or alternative backbone structures, such aspolyamides.

A polynucleotide or polynucleotide region has a certain percentage (forexample, 80%, 85%, 90%, or 95%) of “sequence identity” to anothersequence means that, when aligned, that percentage of bases are the samein comparing the two sequences. This alignment and the percent homologyor sequence identity can be determined using software programs known inthe art, for example, those described in Current Protocols in MolecularBiology (Ausubel et al., eds., 1987), Supp. 30, section 7.7.18, Table7.7.1. A preferred alignment program is ALIGN Plus (Scientific andEducational Software, Pennsylvania).

“Under transcriptional control” is a term well-understood in the art andindicates that transcription of a polynucleotide sequence, usually a DNAsequence, depends on its being operably (operatively) linked to anelement which contributes to the initiation of, or promotes,transcription. As noted below, “operably linked” refers to ajuxtaposition wherein the elements are in an arrangement allowing themto function.

The terms “polypeptide”, “oligopeptide”, “peptide” and “protein” areused interchangeably herein to refer to polymers of amino acids of anylength. The polymer may be linear or branched, it may comprise modifiedamino acids, it may be interrupted by non-amino acids, and it may beassembled into a complex of more than one polypeptide chain. The termsalso encompass an amino acid polymer that has been modified naturally orby intervention; for example, disulfide bond formation, glycosylation,lipidation, acetylation, phosphorylation, or any other manipulation ormodification, such as conjugation with a labeling component. Alsoincluded within the definition are, for example, polypeptides containingone or more analogs of an amino acid (including, for example, unnaturalamino acids, etc.), as well as other modifications known in the art.

In the context of polypeptides, a “linear sequence” or a “sequence” isan order of amino acids in a polypeptide in an N-terminal to C-terminaldirection in which residues that neighbor each other in the sequence arecontiguous in the primary structure of the polypeptide. A “partialsequence” is a linear sequence of part of a polypeptide which is knownto comprise additional residues in one or both directions.

A polypeptide “fragment” (also called a “region”) of ADP (or a “ADPfragment” or “ADP region”) is a polypeptide comprising an amino acidsequence of ADP that has at least 5 contiguous amino acids of a sequenceof ADP, more preferably at least 10 contiguous amino acids, morepreferably at least about 15 contiguous amino acids, even morepreferably at least about 25 contiguous amino acids, even morepreferably at least about 30 contiguous amino acids, even morepreferably at least about 40 contiguous amino acids. An ADP fragment maybe characterized as having any of the functions attributed to ADP,including those described herein.

“Replication” and “propagation” are used interchangeably and refer tothe ability of an adenovirus vector of the invention to reproduce, orproliferate. This term is well understood in the art. For purposes ofthis invention, replication involves production of adenovirus proteinsand is generally directed to reproduction of adenovirus. Replication canbe measured using assays standard in the art and described herein, suchas a burst assay, plaque assay, or a one-step growth curve assay.“Replication” and “propagation” include any activity directly orindirectly involved in the process of virus manufacture, including, butnot limited to, viral gene expression; production of viral proteins,nucleic acids or other components; packaging of viral components intocomplete viruses; and cell lysis.

As used herein, “cytotoxicity” is a term well understood in the art andrefers to a state in which one or more of a cell's usual biochemical orbiological functions are aberrantly compromised (i.e., inhibited orelevated). These activities include, but are not limited to, metabolism;cellular replication; DNA replication; transcription; translation; anduptake of molecules. “Cytotoxicity” includes cell death and/orcytolysis. Assays are known in the art which indicate cytotoxicity, suchas dye exclusion, ³H-thymidine uptake, and plaque assays. The term“selective cytotoxicity”, as used herein, refers to the cytotoxicityconferred by an adenovirus vector of the present invention on a cellwhich allows an AFP-TRE to function when compared to the cytotoxicityconferred by the adenovirus on a cell which does not allow an AFP-TRE tofunction. Such cytotoxicity may be measured, for example, by plaqueassays, or the reduction or stabilization in size of a tumor comprisingtarget cells, or the reduction or stabilization of serum levels of amarker characteristic of the tumor cells or a tissue-specific marker,e.g., a cancer marker such as AFP or prostate-specific antigen.

A “heterologous gene” or “transgene” is any gene that is not present inwild-type adenovirus. Preferably, the transgene will also not beexpressed or present in the target cell prior to introduction by theadenovirus vector. Examples of preferred transgenes are provided below.

A “heterologous” promoter or enhancer is one which is not associatedwith or derived from an AFP gene 5′ flanking sequence. Examples of aheterologous promoter or enhancer are the albumin promoter or enhancerand other viral promoters and enhancers, such as SV40.

An “endogenous” promoter, enhancer, or TRE is native to or derived fromadenovirus.

The term “operably linked” relates to the orientation of polynucleotideelements in a functional relationship. A TRE is operably linked to acoding segment if the TRE promotes transcription of the coding sequence.Operably linked means that the DNA sequences being linked are generallycontiguous and, where necessary to join two protein coding regions,contiguous and in the same reading frame. However, since enhancersgenerally function when separated from the promoter by several kilobasesand intronic sequences may be of variable length, some polynucleotideelements may be operably linked but not contiguous.

A “host cell” includes an individual cell or cell culture which can beor has been a recipient of an adenoviral vector(s) of this invention.Host cells include progeny of a single host cell, and the progeny maynot necessarily be completely identical (in morphology or in total DNAcomplement) to the original parent cell due to natural, accidental, ordeliberate mutation and/or change. A host cell includes cellstransfected or infected in vivo or in vitro with an adenoviral vector ofthis invention.

A “target cell” is any cell that allows an AFP-TRE to function.Preferably, a target cell is a mammalian cell, preferably a mammalianAFP-expressing cell, more preferably, a human cell expressing AFP.

As used herein, “neoplastic cells,” “neoplasia,” “tumor,” “tumor cells,”“cancer” and “cancer cells” (used interchangably) refer to cells whichexhibit relatively autonomous growth, so that they exhibit an aberrantgrowth phenotype characterized by a significant loss of control of cellproliferation. Neoplastic cells can be benign or malignant.

As used herein, “a cell which allows an AFP-TRE to function”, a cell inwhich the function of an AFP-TRE is “sufficiently preserved”, “a cell inwhich an AFP-TRE is functional”, or the like is a cell in which anAFP-TRE, when operably linked to, for example, a reporter gene,increases expression of the reporter gene at least about 2-fold,preferably at least about 5-fold, preferably at least about 10-fold,more preferably at least about 20-fold, more preferably at least about50-fold, more preferably at least about 100-fold, more preferably atleast about 200-fold, even more preferably at least about 400- to500-fold, even more preferably at least about 1000-fold, when comparedto the expression of the same reporter gene when not linked to theAFP-TRE. Methods for measuring levels (whether relative or absolute) ofexpression are known in the art and are described herein.

A “non-naturally occurring” or “recombinant” adenoviral vector are usedinterchangably and mean that an adenoviral vector which either does notoccur in nature or contains polynucleotide elements (or components)which are in an arrangement not found in nature. As discussed herein, inthe context of adenoviral vectors containing coding sequence(s) for ADP,the term encompasses those adenoviral vectors that are non-naturallyoccurring or recombinant due to manipulations involving ADP sequencesand/or those manipulations not involving ADP sequences. For example, anon-naturally occurring adenoviral vector comprising an ADP codingsequence may have contained the ADP coding sequence prior to anymanipulation but has been rendered non-naturally occurring due toinsertion and/or deletion of other sequence element(s). For example,such an adenoviral vector may comprise a cell specific TRE regulatingtranscription of an early gene in an adenoviral vector that alsocontains and ADP encoding sequence. As another example, a non-naturallyoccurring adenoviral vector may arise by adding an ADP encoding sequenceto an adenoviral vector which did not contain such a sequence (seeExample 5).

An “ADP coding sequence” is a polynucleotide that encodes ADP or afunctional fragment thereof. In the context of ADP, a “functionalfragment” of ADP is one that exhibits cytotoxic activity, especiallycell lysis, with respect to adenoviral replication. Ways to measurecytotoxic activity are known in the art and are described herein.

A polynucleotide that “encodes” an ADP polypeptide is one that can betranscribed and/or translated to produce an ADP polypeptide or afragment thereof. The anti-sense strand of such a polynucleotide is alsosaid to encode the sequence.

An “ADP polypeptide” is a polypeptide containing at least a portion, orregion, of the amino acid sequence of an ADP (see, for example, SEQ IDNO: 23), and which displays a function associated with ADP, particularlycytotoxicity, more particularly, cell lysis. As discussed herein, thesefunctions can be measured using techniques known in the art. It isunderstood that certain sequence variations may be used, due to, forexample, conservative amino acid substitutions, which may provide ADPpolypeptides.

A polynucleotide or polypeptide sequence that is “depicted in” a SEQ IDNO means that the sequence is present as an identical contiguoussequence in the SEQ ID NO. The term encompasses portions, or regions ofthe SEQ ID NO as well as the entire sequence contained within the SEQ IDNO.

A “biological sample” encompasses a variety of sample types obtainedfrom an individual and can be used in a diagnostic or monitoring assay.The definition encompasses blood and other liquid samples of biologicalorigin, solid tissue samples such as a biopsy specimen or tissuecultures or cells derived therefrom, and the progeny thereof. Thedefinition also includes samples that have been manipulated in any wayafter their procurement, such as by treatment with reagents,solubilization, or enrichment for certain components, such as proteinsor polynucleotides. The term “biological sample” encompasses a clinicalsample, and also includes cells in culture, cell supernatants, celllysates, serum, plasma, biological fluid, and tissue samples.

An “individual” is a vertebrate, preferably a mammal, more preferably ahuman. Mammals include, but are not limited to, farm animals, sportanimals, and pets.

An “effective amount” is an amount sufficient to effect beneficial ordesired clinical results. An effective amount can be administered in oneor more administrations. For purposes of this invention, an effectiveamount of an adenoviral vector is an amount that is sufficient topalliate, ameliorate, stabilize, reverse, slow or delay the progressionof the disease state.

As used herein, “treatment” is an approach for obtaining beneficial ordesired clinical results. For purposes of this invention, beneficial ordesired clinical results include, but are not limited to, alleviation ofsymptoms, diminishment of extent of disease, stabilized (i.e., notworsening) state of disease, preventing spread (i.e., metastasis) ofdisease, delay or slowing of disease progression, amelioration orpalliation of the disease state, and remission (whether partial ortotal), whether detectable or undetectable. “Treatment” can also meanprolonging survival as compared to expected survival if not receivingtreatment.

“Palliating” a disease means that the extent and/or undesirable clinicalmanifestations of a disease state are lessened and/or time course of theprogression is slowed or lengthened, as compared to riot administeringadenoviral vectors of the present invention.

Adenoviral Vectors Having Replication Specificity for AFP-producingCells

The present invention provides adenoviral vector constructs whichcomprise an adenoviral gene under transcriptional control of an AFP-TRE.Preferably, the advenovirus gene contributes to cytotoxicity (whetherdirect and/or indirect), more preferably one that contributes to orcauses cell death, even more preferably is essential for advenoviralreplication. Examples of a gene that contributes to cytotoxicityinclude, but are not limited to, advenovirus death protein (ADP;discussed below). When the adenovirus vector(s) is selectively (i.e.,preferentially) replication competent for propagation in target cellsexpressing AFP, these cells will be preferentially killed uponadenoviral proliferation. By combining the adenovirus vector(s) with amixture of malignant and normal liver cells, for example, in vitro or invivo, the adenovirus vector(s) will preferentially replicate in thetarget malignant liver cells. Once the target cells are destroyed due toselective cytotoxic and/or cytolytic replication, the adenovirus vectorreplication is significantly reduced, thus lessening the probability ofrunaway infection and undesirable bystander effects. In vitro culturesmay be retained to monitor the mixture (such as, for example, a biopsyor other appropriate biological sample) for occurrence (i.e., presence)and/or recurrence of the target cell, e.g., an AFP-producing neoplasticcell. To further ensure cytotoxicity, one or more transgenes having acytotoxic effect may also be present and under selective transcriptionalcontrol. In this embodiment, one may provide higher confidence that thetarget cells will be destroyed. Additionally, or alternatively, anadenovirus gene that contributes to cytotoxicity and/or cell death (suchas ADP) may be included in the adenoviral vector, either free of, orunder, selective transcriptional control.

The AFP-TREs used in this invention are derived from mammalian cells,including but not limited to, human, rat, and mouse. Rodent and humanAFP 5′ flanking sequences have been described in the literature and arethus made available for practice of this invention and need not bedescribed in detail herein. Rat AFP 5′ flanking sequences have beendescribed and characterized. Wen et al. (1991) DNA Cell Biol.10:525-536; Wen et al. (1993) Nucl. Acids Res. 21:1911-1918. The rat AFP5′ flanking region contains three upstream enhancers denoted complex 1(from −2800 to −2400), complex 2 (from −4500 to −3500), and complex 3(from −7000 to 4900). The promoter region encompasses −250 to −1; thepromoter element from −178 to −155 is required if the enhancers aredistant but is dispensable if the enhancer(s) is closer. Wen et al.(1991 and 1993). Groupp et al. (1994) report activity of complex 3 (on a344 bp HincII fragment), the most distal enhancer element. J. Biol.Chem. 269:22178-22187. Arbuthnot et al. (1996) showed activity ofsequences −3127 to +102, which encompass the most proximal enhancer andpromoter (and region homologous to the mouse silencer sequence) in humanhepatoma cell lines HuH7, Hep 3B, and HepG2.

Mouse 5′ flanking AFP sequences have been described and characterized.Ghebranious et al. (1995) Mol. Reprod. Devel. 42:1-6. Like rat, mouse 5′flanking AFP sequences contain three separate enhancer elements. Asilencer, or element associated with shut off in the adult liver, isfound between −838 and −250. Emerson et al. (1992) Devel. Dynam.195:55-66.

Preferably, the AFP-TRE is human. The cloning and characterization ofAFP-specific enhancer activity is described in Watanabe et al. (1987).The entire 5′ AFP flanking region (containing the promoter, putativesilencer, and enhancer elements) is contained within approximately 5 kbupstream from the transcription start site. The AFP enhancer region inhuman is located between about −3954 and about −3335, relative to thetranscription start (CAP) site of the AFP gene. The human AFP promoterencompasses a region from about −174 to about +29. Ido et al. (1995)describe a 259 bp promoter fragment (−230+29) that is specific for HCC.Cancer Res. 55:3105-3109. The AFP enhancer contains two regions, denotedA and B, located between −3954 and −3335 relative to the transcriptionstart site. The promoter region contains typical TATA and CAAT boxes.Preferably, the AFP-TRE contains at least one enhancer region. Morepreferably, the AFP-TRE contains both enhancer regions.

Kaneko et al. (1995) have used a 4.9 kb HindIII to HindIII fragment.Kanai et al. (1995 and 1996) have shown activity on a shorter fragmentwhich contained a 0.2 kb (BglII to HindIII) promoter segment and asegment containing enhancers A and B (−4.0 to −3.3 kb; ApaI to BglII).

In one embodiment, the AFP-TRE comprises an approximately 0.6 kbenhancer region (from −3954 to −3335) and a 0.2 kb promoter region (−174to +29), both of which are specific for AFP-producing cells as shown inFIG. 1B. Juxtaposition of these two genetic elements yields a fullyfunctional AFP-TRE (Example 1). Accordingly, the invention also includesan adenovirus vector in which the AFP-TRE comprises SEQ ID NO: 1 (i.e.,the sequence of SEQ ID NO: 1).

In another embodiment, the AFP-TRE comprises the sequence from about +1to about +600 of SEQ ID NO: 1. This embodiment thus comprises enhancerregions A and B. In another embodiment, the AFP-TRE comprises thesequence from about +600 to about +827 of SEQ ID NO: 1, thus comprisingthe AFP promoter. The enhancer region may be further subdivided (regionsA and B); thus, further embodiments include: (a) an AFP-TRE thatcomprises nucleotide sequence from about +1 to about +300 of SEQ ID NO:1; (b) an AFP-TRE that comprises nucleotide sequence from about +300 toabout +600 of SEQ ID NO: 1.

In another embodiment, the AFP-TRE contains the entire 5.1 kb 5′flanking sequence (SEQ ID NO: 2).

An AFP-TRE can also comprise multimers. For example, an AFP-TRE cancomprise a tandem series of at least two, at least three, at least four,or at least five AFP promoter fragments. Alternatively, an AFP-TRE couldhave one or more AFP promoter regions along with one or more AFPenhancer regions. These multimers may also contain heterologous promoterand/or enhancer sequences.

An AFP-TRE may or may not lack a silencer. The presence of a silencer(i.e., a negative regulatory element) may assist in shutting offtranscription (and thus replication) in non-permissive (i.e.,non-AFP-producing) cells. Thus, presence of a silencer may conferenhanced cell-specific replication by more effectively preventingadenoviral vector replication in non-target cells. Alternatively, lackof a silencer may assist in effecting replication in target cells, thusconferring enhanced cell-specific replication due to more effectivereplication in target cells. The 5′ flanking region of the AFP gene hasbeen shown to contain two silencer elements, from −1822 to −951 (distalelement) and from −402 to −169 (proximal element). Nakabayashi et al.(1991) Mol. Cell. Biol. 11:5885-5893. Kanai et al. (1995) have reportedthe activity of a fragment lacking the silencer is higher than reportedactivities for the approximately 5.0 kb native 5′ flanking region.

As is readily appreciated by one skilled in the art, an AFP-TRE is apolynucleotide sequence, and, as such, can exhibit function over avariety of sequence permutations. Methods of nucleotide substitution,addition, and deletion are known in the art, and readily availablefunctional assays (such as the CAT or luciferase reporter gene assay)allow one of ordinary skill to determine whether a sequence variantexhibits requisite cell-specific transcription function. Hence, theinvention also includes functionally-preserved variants of the nucleicacid sequences disclosed herein, which include nucleic acidsubstitutions, additions, and/or deletions. While not wishing to bebound by a single theory, the inventors note that it is possible thatcertain modifications will result in modulated resultant expressionlevels, including enhanced expression levels. Achievement of modulatedresultant expression levels, preferably enhanced expression levels, maybe especially desirable in the case of certain, more aggressive forms ofhepatoma, or when a more rapid and/or aggressive pattern of cell killingis warranted (due to an immunocompromised condition of the individual,for example).

As an example of how AFP-TRE activity can be determined, apolynucleotide sequence or set of such sequences can be generated usingmethods known in the art, such as chemical synthesis, site-directedmutagenesis, PCR, and/or recombinant methods. The sequence(s) to betested is inserted into a vector containing an appropriate reportergene, including, but not limited to, chloramphenicol acetyl transferase(CAT), β-galactosidase (encoded by the lacZ gene), luciferase (encodedby the luc gene), green fluorescent protein, alkaline phosphatase, andhorse radish peroxidase. Such vectors and assays are readily available,from, inter alia, commercial sources. Plasmids thus constructed aretransfected into a suitable host cell to test for expression of thereporter gene as controlled by the putative AFP-TRE using transfectionmethods known in the art, such as calcium phosphate precipitation,electroporation, liposomes (lipofection), and DEAE-dextran. Suitablehost cells include any cell type that produces AFP, including but notlimited to, Hep3B, Hep G2, HuH7, HuH1/C12 and AFP-SK-Hep-1. Non-AFPproducing cells, such as LNCaP, HBL-100, Chang liver cells, MCF-7, HLF,HLE, 3T3, and HeLa are used as a control. Results are obtained bymeasuring the level of expression of the reporter gene using standardassays. Comparison of expression between AFP-producing cells and controlindicates presence or absence of transcriptional activation. Example 2describes an experiment in which an 800 bp putative AFP-TRE (a 0.6 kbenhancer region fused to a 0.2 kb promoter region, as described above)was tested using a luciferase reporter assay.

By transcriptional increase or activation, it is intended thattranscription is increased above basal levels in the target cell (i.e.,AFP-producing cell) by at least about 2 fold, preferably at least about5 fold, preferably at least about 10 fold, more preferably at leastabout 20 fold, more preferably at least about 50 fold, more preferablyat least about 100 fold, more preferably at least about 200 fold, evenmore preferably at least about 400 fold to about 500 fold, even morepreferably at least about 1000 fold. Comparisons between or amongvarious AFP-TREs can be assessed by measuring and comparing levels ofexpression within a single AFP-producing cell line. It is understoodthat absolute transcriptional activity of an AFP-TRE will depend onseveral factors, such as the nature of the target cell, delivery modeand form of the AFP-TRE, and the coding sequence that is to beselectively transitionally activated. To compensate for various plasmidsizes used, activities can be expressed as relative activity per mole oftransfected plasmid. Alternatively, the level of transcription (i.e.,mRNA) can be measured using standard Northern analysis and hybridizationtechniques. Levels of transfection (i.e., transfection efficiencies) aremeasured by co-transfecting a plasmid encoding a different reporter geneunder control of a different TRE, such as the cytomegalovirus (CMV)immediate early promoter. This analysis can also indicate negativeregulatory regions, i.e., silencers.

Alternatively a putative AFP-TRE can be assessed for its ability toconfer adenoviral replication preference for cells expressing AFP. Forthis assay, constructs containing an adenovirus gene essential toreplication operatively linked to a putative AFP-TRE are transfectedinto cells that express AFP. Viral replication in those cells iscompared, for example, to viral replication by the construct in cellsnot producing AFP. A more detailed description of this kind of assay isin Example 1.

It is understood that, to practice this invention, it is not necessaryto use AFP-TREs having maximum activity, or having minimum size. Therequisite degree of activity is determined, inter alia, by theanticipated use and desired result. For example, if an adenoviral vectorof the invention is used to monitor cells for AFP-producing activity, itis possible that less than maximal degree of responsiveness by anAFP-TRE will suffice to indicate qualitatively the presence of suchcells. Similarly, if used for treatment or palliation of a diseasestate, less-than-maximal responsiveness may be sufficient for thedesired result, if, for example, the AFP-producing cells are notespecially virulent and/or the extent of disease is relatively confined.

The size of AFP-TREs will be determined in part by the capacity of theadenoviral vector, which in turn depends upon the contemplated form ofthe vector (see below). Generally a minimal size is preferred, as thisprovides potential room for insertion of other sequences which may bedesirable, such as transgenes (discussed below) or additional regulatorysequences. However, if no additional sequences are contemplated, or if,for example, an adenoviral vector will be maintained and delivered freeof any viral packaging constraints, a larger AFP-TRE may be used as longas the resultant adenoviral vector is rendered replication competent.

If no adenovirus sequences have been deleted, an adenoviral vector canbe packaged with extra sequences totaling up to about 5% of the genomesize, or approximately 1.8 kb. If non-essential sequences are removedfrom the adenovirus genome, then an additional 4.6 kb of insert can betolerated (i.e., a total of about 1.8 kb plus 4.6 kb, which is about 6.4kb). Examples of non-essential adenoviral sequences that can be deletedare E3 and E4 (as long as E4 ORF6 is maintained).

Because AFP-specific transcriptional activity has been shown in a 5.1 kb5′ flanking fragment, and AFP-TRE can be at least as large as about 5.0kb. Preferably, an AFP-TRE will comprise a polynucleotide sequence ofabout 2.5 kb, more preferably about 1 kb, more preferably about 0.8 kb,even more preferably about 0.5 kb, even more preferably about 0.3 kb(which is the approximate size of one of the AFP enhancer elements).

Various replication-competent adenovirus vectors can be made accordingto the present invention in which a single or multiple adenovirusgene(s) is under control of an AFP-TRE. For example, an AFP-TRE may beintroduced into an adenovirus vector immediately upstream of andoperably linked to a replication gene, e.g., an early gene such as E1A,E1B or E4, or a late gene such as L1, L2, L3, L4, or L5. In someembodiments, the adenoviral vectors comprise an E1A gene undertranscriptional control of an AFP-TRE. In other embodiments, theadenoviral vectors comprise an E1B gene under transcriptional control ofan AFP-TRE. In other embodiments, the adenoviral vectors comprise an E4gene under transcriptional control of an AFP-TRE. In other embodiments,various combinations and permutations of the above may be practiced. Forexample, in some embodiments, the adenoviral vectors comprise an E1Agene under transcriptional control of an AFP-TRE, and E1B gene undertranscriptional control of an AFP-TRE (i.e., a “double” AFP-TREconstruct”). In other embodiments, the adenoviral vectors comprise anE1A gene under transcriptional control of an AFP-TRE, an E1B gene undertranscriptional control of a second AFP-TRE, and an E4 gene undertranscriptional control of a third AFP-TRE. “First”, “second”, “third”,and the like AFP-TREs in this context means that separate AFP-TREs driveeach respective gene. The AFP-TREs used may or may not have the samesequence composition. However, as described elsewhere, it is alsopossible to have a single AFP-TRE regulate transcription of more thanone adenovirus gene.

In one embodiment, E1A and E1B are under control of one or more AFP-TREsby making the following construct. In wild-type adenovirus, E1A and E1Bare in tandem orientation. A fragment containing the coding region ofE1A through the E1B promoter is excised from the adenovirus genome andreinserted in the opposite orientation (FIG. 4). In this configuration,the E1A and E1B promoters are next to each other, followed by E1A codingsegment in opposite orientation (so that neither the E1A or E1Bpromoters are operably linked to E1A), followed by E1B in oppositeorientation with respect to E1A. An AFP-TRE(s) can be inserted betweenE1A and E1B coding regions, (which are in opposite orientation), so thatthese regions are under control of the TRE(s). Appropriate promotersequences are inserted proximal to the E1A and E1B region as shown inFIG. 4. Thus, an AFP-TRE may drive both E1A and E1B. Such aconfiguration may prevent, for example, possible loop-out events thatmay occur if two AFP-TREs were inserted in intact (native) Ad genome,one each 5′ of the coding regions of E1A and E1B. By introducing apolycloning site between E1A and E1B, other types of AFP, orliver-specific TREs can be inserted, or other cell-specific regulatoryelements, preferably those associated with a disease state, such asneoplasm. Thus, this construct may find general use for cell-specific,temporal, or other means of control of adenovirus genes E1A and E1B,thereby providing a convenient and powerful way to render adenoviralreplication dependent upon a chosen transcriptional parameter.

Various other replication-competent adenovirus vectors can be madeaccording to the present invention in which, in addition to having asingle or multiple adenovirus gene(s) are under control of an AFP-TRE,reporter gene(s) are under control of an AFP-TRE.

For example, an AFP-TRE may be introduced into an adenovirus vectorimmediately upstream of and operably linked to an early gene such as E1Aor E1B, and this construct may also contain a second AFP-TRE drivingexpression of a reporter gene. The reporter gene can encode a reporterprotein, including, but not limited to, chloramphenicol acetyltransferase (CAT), β-galactosidase (encoded by the lacZ gene),luciferase, alkaline phosphatase, green fluorescent protein, and horseradish peroxidase. For detection of a putative prostate cell(s) in abiological sample, the biological sample may be treated with modifiedadenoviruses in which a reporter gene (e.g., luciferase) is undercontrol of an AFP-TRE. The AFP-TRE will be transcriptionally active incells which allow the AFP-TRE to function (such as AFP-expressingcells), and luciferase will be produced. This production allowsdetection of cells producing androgen receptor in, for example, a humanhost or a biological sample. Alternatively, an adenovirus vector can beconstructed in which the gene encoding a product conditionally requiredfor survival (e.g., an antibiotic resistance marker) is under control ofan AFP-TRE. When this adenovirus vector is introduced into a biologicalsample, cells which allow an AFP-TRE to function, such as AFP-expressingcells, will become antibiotic resistant. An antibiotic can then beintroduced into the medium to kill non-androgen receptor producingcells.

In order to minimize non-specific replication, endogenous (i.e.,adenovirus) TRE's should preferably be removed. This would also providemore room for inserts in an adenoviral vector, which may be of especialconcern if an adenoviral vector will be packaged as a virus (see below).Even more importantly, deletion of endogenous TREs would prevent apossibility of a recombination event whereby an AFP-TRE is deleted andthe endogenous TRE assumes transcriptional control of its respectiveadenovirus coding sequences (thus allowing non-specific replication). Inone embodiment, an adenoviral vector of the invention is constructedsuch that the endogenous transcription control sequences of anadenoviral gene(s) are deleted and replaced by an AFP-TRE. However,endogenous TREs may also be maintained in the adenovirus vector(s),provided that sufficient cell-specific replication preference ispreserved. These embodiments can be constructed by providing an AFP-TREin addition to the endogenous TREs, preferably with the AFP-TREintervening between the endogenous TREs and replication gene codingsegment. Requisite cell-specific replication preference is indicated byconducting assays that compare replication of the adenovirus vector in acell expressing AFP with replication in a non-AFP producing cell.Generally, a replication differential of at least about 2-fold ispreferred; more preferably, at least about 5-fold; more preferably, atleast about 10-fold; more preferably, at least about 50-fold; even morepreferably, at least about 100-fold; still more preferably, at leastabout 200-fold; still more preferably, at least about 400-fold to about500-fold; even more preferably, at least about 1000-fold. The acceptabledifferential can be determined empirically (using, for example, assaysdescribed in the Example section) and will depend upon the anticipateduse of the adenoviral vector and/or the desired result.

Suitable target cells are any cell type that allows an AFP-TRE tofunction. Preferred are cells that express, or produce, or are capableof expressing or producing AFP, including, but not limited to, tumorcells expressing AFP. Examples of such cells are hepatocellularcarcinoma cells, gonadal and other germ cell tumors (especiallyendodermal sinus tumors), brain tumor cells, ovarian tumor cells, acinarcell carcinoma of the pancreas (Kawamoto et al. (1992)Hepatogastroenterology 39:282-286), primary gall bladder tumor (Katsuragi et al. (1989) Rinsko Hoshasen 34:371-374), uterine endometrialadenocarcinoma cells (Koyama et al. (1996) Jpn. J. Cancer Res.87:612-617), and any metastases of the foregoing (which can occur inlung, adrenal gland, bone marrow, and/or spleen). In some cases,metastatic disease to the liver from certain pancreatic and stomachcancers produce AFP. Especially preferred are hepatocellular carcinomacells and any of their metastases. AFP production can be measured usingassays standard in the art, such as RIA, ELISA or Western blots(immunoassays) to determine levels of AFP protein production or Northernblots to determine levels of AFP mRNA production. Alternatively, suchcells can be identified and/or characterized by their ability toactivate transcriptionally an AFP-TRE (i.e., allow an AFP-TRE tofunction).

Any of the various serotypes of adenovirus can be used, such as Ad2,Ad5, Ad12 and Ad40. For purposes of illustration, serotype Ad5 will beexemplified herein.

In some embodiments, an AFP-TRE is used with an adenovirus gene that isessential for propagation, so that replication competence ispreferentially achievable in the target cell expressing AFP. Preferably,the gene is an early gene, such as E1A, E1B, E2, or E4. (E3 is notessential for viral replication.) More preferably, the early gene underAFP-TRE control is E1A and/or E1B and/or E4. More than one early genecan be placed under control of an AFP-TRE. Example 1 provides a moredetailed description of such constructs.

The E1A gene is expressed immediately after viral infection (0-2 h) andbefore any other viral genes. E1A protein acts as a trans-actingpositive-acting transcriptional regulatory factor, and is required forthe expression of the other early viral genes E1B, E2, E3, E4, and thepromoter-proximal major late genes. Despite the nomenclature, thepromoter proximal genes driven by the major late promoter are expressedduring early times after Ad5 infection. Flint (1982) Biochem. Biophys.Acta 651:175-208; Flint (1986) Advances Virus Research 31:169-228; Grand(1987) Biochem. J. 241:25-38. In the absence of a functional E1A gene,viral infection does not proceed, because the gene products necessaryfor viral DNA replication are not produced. Nevins (1989) Adv. VirusRes. 31:35-81. The transcription start site of Ad5 E1A is at 498 and theATG start site of the E1A protein is at 560 in the virus genome.

The E1B protein functions in trans and is necessary for transport oflate mRNA from the nucleus to the cytoplasm. Defects in E1B expressionresult in poor expression of late viral proteins and an inability toshut off host cell protein synthesis. The promoter of E1B has beenimplicated as the defining element of difference in the host range ofAd40 and Ad5: clinically Ad40 is an enterovirus, whereas Ad5 causesacute conjunctivitis. Bailey, Mackay et al. (1993) Virology 193:631;Bailey et al. (1994) Virology 202:695-706). The E1B promoter of Ad5consists of a single high-affinity recognition site for Spl and a TATAbox.

The E2 region of adenovirus codes for proteins related to replication ofthe adenoviral genome, including the 72 kDa DNA-binding protein, the 80kD precursor terminal protein and the viral DNA polymerase. The E2region of Ad5 is transcribed in a rightward orientation from twopromoters, termed E2 early and E2 late, mapping at 76.0 and 72.0 mapunits, respectively. While the E2 late promoter is transiently activeduring late stages of infection and is independent of the E1atransactivator protein, the E2 early promoter is crucial during theearly phases of viral replication.

The E2 early promoter, mapping in Ad5 from 27050-27150, consists of amajor and a minor transcription initiation site, the latter accountingfor about 5% of the E2 transcripts, two non-canonical TATA boxes, twoE2F transcription factor binding sites and an ATF transcription factorbinding site.

For a detailed review of the E2 promoter architecture see Swaminathan etal., Curr. Topics in Micro. and Imm. (1995) 199 part 3:177-194.

The E2 late promoter overlaps with the coding sequences of a geneencoded by the counterstrand and is therefore not amenable to geneticmanipulation. However, the E2 early promoter overlaps only for a fewbase pairs with sequences coding for a 33 kD protein on thecounterstrand. Notably, the SpeI restriction site (Ad5 position 27082)is part of the stop codon for the above mentioned 33 kD protein andconveniently separates the major E2 early transcription initiation siteand TATA-binding protein site from the upstream transcription factorbiding sites E2F and ATF. Therefore, insertion of an AFP-TRE having SpeIends into the SpeI site in the 1-strand would disrupt the endogenous E2early promoter of Ad5 and should allow AFP-restricted expression of E2transcripts.

The E4 gene has a number of transcription products. The E4 region codesfor two polypeptides which are responsible for stimulating thereplication of viral genomic DNA and for stimulating late geneexpression. The protein products of open reading frames (ORFS) 3 and 6can both perform these functions by binding the 55 kD protein from E1Band heterodimers of E2F-1 and DP-1. The ORF 6 protein requiresinteraction with the E1B 55 kD protein for activity while the ORF 3protein does not. In the absence of functional protein from ORF 3 andORF 6, plaques are produced with an efficiency less than 10⁻⁶ that ofwild type virus. To further restrict viral replication to AFP-producingcells, E4 ORFs 1-3 can be deleted, making viral DNA replication and lategene synthesis dependent on E4 ORF 6 protein. By combining such a mutantwith sequences in which the E1B region is regulated by an AFP-TRE, avirus can be obtained in which both the E1B function and E4 function aredependent on an AFP-TRE driving E1B.

The major late genes relevant to the subject invention are genes L1, L2,L3, L4, and L5 which encode proteins of the adenovirus virion. All ofthese genes (typically coding for structural proteins) are probablyrequired for adenoviral replication. The late genes are all under thecontrol of the major late promoter (MLP), which is located in Ad5 at+5986 to +6048.

In addition to conferring selective cytotoxic and/or cytolytic activityby virtue of preferential replication competence in cells that allow anAFP-TRE to function, such as cells expressing AFP, the adenovirusvectors of this invention can further include a heterologous gene(transgene) under the control of an AFP-TRE. In this way, variousgenetic capabilities may be introduced into target cells expressing AFP,particularly AFP-producing cancer cells. For example, in certaininstances, it may be desirable to enhance the degree and/or rate ofcytotoxic activity, due to, for example, the relatively refractorynature or particular aggressiveness of the AFP-producing target cell.This could be accomplished by coupling the cell-specific replicativecytotoxic activity with cell-specific expression of, for example, HSV-tkand/or cytosine deaminase (cd), which renders cells capable ofmetabolizing 5-fluorocytosine (5-FC) to the chemotherapeutic agent5-fluorouracil (5-FU). Using these types of transgenes may also confer abystander effect.

Other desirable transgenes that may be introduced via an adenovirusvector(s) include genes encoding cytotoxic proteins, such as the Achains of diphtheria toxin, ricin or abrin [Palmiter et al. (1987) Cell50: 435; Maxwell et al. (1987) Mol. Cell. Biol. 7: 1576; Behringer etal. (1988) Genes Dev. 2: 453; Messing et al. (1992) Neuron 8: 507;Piatak et al. (1988) J. Biol. Chem. 263: 4937; Lamb et al. (1985) Eur.J. Biochem. 148: 265; Frankel et al. (1989) Mol. Cell. Biol. 9: 415],genes encoding a factor capable of initiating apoptosis, sequencesencoding antisense transcripts or ribozymes, which among othercapabilities may be directed to mRNAs encoding proteins essential forproliferation, such as structural proteins, or transcription factors;viral or other pathogenic proteins, where the pathogen proliferatesintracellularly; genes that encode an engineered cytoplasmic variant ofa nuclease (e.g. RNase A) or protease (e.g. awsin, papain, proteinase K,carboxypeptidase, etc.), or encode the Fas gene, and the like. Othergenes of interest include cytokines, antigens, transmembrane proteins,and the like, such as IL-1, -2, -6, -12, GM-CSF, G-CSF, M-CSF, IFN-α,-β, -γ, TNF-α, -β, TGF-α, -β, NGF, and the like. The positive effectorgenes could be used in an earlier phase, followed by cytotoxic activitydue to replication.

As discussed above, in some embodiments, the adenovirus death protein(ADP), encoded within the E3 region, is maintained (i.e., contained) inthe adenovirus vector. The ADP gene, under control of the major latepromoter (MLP), appears to code for a protein (ADP) that is important inexpediting host cell lysis. Tollefson et al. (1996) J. Virol.70(4):2296; Tollefson et al. (1992) J. Virol. 66(6):3633. Thus,adenoviral vectors containing the ADP gene may render the adenoviralvector more potent, making possible more effective treatment and/or alower dosage requirement.

Accordingly, the invention provides adenoviral vectors that include apolynucleotide sequence encoding an ADP. A DNA sequence encoding an ADPand the amino acid sequence of an ADP are depicted in SEQ ID NO: 22 andSEQ ID NO: 23, respectively. Briefly, an ADP coding sequence is obtainedpreferably from Ad2 (since this is the strain in which ADP has been morefully characterized) using techniques known in the art, such as PCR.Preferably, the Y leader (which is an important sequence for correctexpression of late genes) is also obtained and ligated to the ADP codingsequence. The ADP coding sequence (with or without the Y leader) canthen be introduced into the adenoviral genome, for example, in the E3region (where the ADP coding sequence will be driven by the MLP or theE3 promoter). The ADP coding sequence could also be inserted in otherlocations of the adenovirus genome, such as the E4 region.Alternatively, the ADP coding sequence could be operably linked to aheterologous promoter (with or without enhancer(s)), including, but notlimited to, another viral promoter, a tissue specific promoter such asAFP, carcinoembryonic antigen (CEA), mucin, and rat probasin. Example 4provides a description of an ADP construct in which the coding sequencefor ADP was inserted into the E3 region of Ad5.

With respect to ADP, the cytotoxic properties, virus yield, and in vivocytotoxic properties of an adenoviral vector that contains ADP encodingsequences were examined. The viral construct characterized, CN751,showed significant, efficient in vitro cell killing and viral yield whencompared to a control vector not containing these sequences. Further,LNCaP (a prostate carcinoma cell line) tumor xenografts in nude miceeither diminished in size or remained the same size (i.e., growth wassuppressed) when compared to tumor size from those mice receivingcontrol adenoviral vector or buffer, with a statistically significantdifference in tumor size between CN751 and control treated tumors afterseven days post-administration. Collectively, these data stronglysuggest that an ADP-containing adenovector is an effective cytotoxicagent.

Accordingly, the invention also provides a non-naturally occurringadenoviral vector comprising a polynucleotide encoding an ADPpolypeptide. It is understood that these vectors may contain multiplecopies of ADP-encoding sequences, and that, if present in multiplecopies, the sequences need not be the same, as long as an ADPpolypeptide is produced from at least two these sequences. As discussedabove, an “ADP polypeptide” is a polypeptide exhibiting at least onefunction associated with ADP, especially a function associated withcytoxicity, preferably cell death. An “ADP polypeptide” includes formsof ADP discussed above, as well as any polypeptide fragment whichexhibits ADP function. Because ADP function is associated with cytotoxicactivity, particularly lysis, a putative ADP polypeptide can be testedby using methods standard in the art, such as plaque assays.

In some embodiments, the ADP polypeptide is a polypeptide sequencedepicted in SEQ ID NO: 23, including the entire sequence of SEQ ID NO:23. In other embodiments, the polynucleotide encoding the ADPpolypeptide is depicted in SEQ ID NO: 22, including the entire sequenceof SEQ ID NO: 22. Given an amino acid sequence of an ADP, it is possibleusing methods known in the art to design polynucleotides that encode forall or a portion of SEQ ID NO: 23 using polynucleotide sequences otherthan that depicted in SEQ ID NO: 22. Further, given tools such asdegenerate probes that are readily made by those skilled in the art, itis possible to obtain and test other ADP sequences from, for example,other adenoviral serotypes.

The ADP-encoding sequence may or may not be under transcriptionalcontrol of a cell-specific, tissue-specific, and/or tumor-specific TRE.In some embodiments, the ADP polypeptide encoding sequence is undertranscriptional control of a cell-specific TRE, such as, for example, anAFP-TRE or a prostate-cell specific TRE. Examples of a prostate-cellspecific TRE is one derived from prostate specific antigen (U.S. Pat.Nos. 5,698,443 and 5,648,478), probasin (described in commonly ownedpatent application U.S. Ser. No. 60/039,762 and U.S. Ser. No.09/033,333, and human kallikrien 2 (described in commonly owned patentapplication U.S. Ser. No. 60/076,545 and U.S. Ser. No. 60/054,523).Other examples of cell-specific TREs are carcinoembryonic antigen andmucin. Description of functional fragments for these and other TREs areavailable in the art.

In some embodiments, the invention provides adenoviral vectors whichcomprise an additional adenovirus gene under transcriptional control ofa second AFP-TRE. Examples of an additional adenovirus gene undertranscriptional control is ADP (discussed above) and genes necessary forreplication, such as early genes. For example, an adenoviral vector canbe constructed such that a first AFP-TRE regulates transcription of oneearly gene, such as E1A or E1B, and a second AFP-TRE regulatestranscription of another early gene. These multiple constructs may bemore desirable in that they provide more than one source of cellspecificity with respect to replication (see Example 1). CN733, such adouble construct, successfully inhibited tumor growth in nude miceharboring HuH7 tumor xenografts (Example 4).

Any of the adenoviral vectors described herein can be used in a varietyof forms, including, but not limited to, naked polynucleotide (usuallyDNA) constructs; polynucleotide constructs complexed with agents tofacilitate entry into cells, such as cationic liposomes or othercationic compounds such as polylysine; packaged into infectiousadenovirus particles (which may render the adenoviral vector(s) moreimmunogenic); packaged into other particulate viral forms such as HSV orAAV; complexed with agents (such as PEG) to enhance or dampen an immuneresponse; complexed with agents that facilitate in vivo transfection,such as DOTMA™, DOTAP™, and polyamines. Thus, the invention alsoprovides an adenovirus capable of replicating preferentially inAFP-producing cells. “Replicating preferentially” means that theadenovirus replicates more in an AFP-producing cell than a nonAFP-producing cell. Preferably, the adenovirus replicates at asignificantly higher level in AFP-producing cells than non-AFP-producingcells; preferably, at least about 2-fold higher, preferably at leastabout 5-fold higher, more preferably at least about 10-fold higher,still more preferably at least about 50-fold higher, even morepreferably at least about 100-fold higher, still more preferably atleast about 400-fold to about 500-fold higher, still more preferably atleast about 1000-fold higher, most preferably at least about 1×10⁶higher. Most preferably, the adenovirus replicates solely inAFP-producing cells (that is, does not replicate or replicates at verylow levels in non AFP-producing cells).

If an adenoviral vector is packaged into an adenovirus, the adenovirusitself may also be selected to further enhance targeting. For example,adenovirus fibers mediate primary contact with cellular receptor(s)aiding in tropism. See, e.g., Amberg et al. (1997) Virol. 227:239-244.If a particular subgenus of an adenovirus serotype displayed tropism fora target cell type and/or reduced affinity for non-target cell types,such subgenus (or subgenera) could be used to further increasecell-specificity of cytoxicity and/or cytolysis.

The adenoviral vectors may be delivered to the target cell in a varietyof ways, including, but not limited to, liposomes, general transfectionmethods that are well known in the art (such as calcium phosphateprecipitation or electroporation), direct injection, and intravenousinfusion. The means of delivery will depend in large part on theparticular adenoviral vector (including its form) as well as the typeand location of the target cells (i.e., whether the cells are in vitroor in vivo).

If used as a packaged adenovirus, adenovirus vectors may be administeredin an appropriate physiologically acceptable carrier at a dose of about10⁴ to about 10¹⁴. The multiplicity of infection will generally be inthe range of about 0.001 to 100. If administered as a polynucleotideconstruct (i.e., not packaged as a virus) about 0.01 μg to about 1000 μgof an adenoviral vector can be administered. The adenoviral vector(s)may be administered one or more times, depending upon the intended useand the immune response potential of the host, and may also beadministered as multiple, simultaneous injections. If an immune responseis undesirable, the immune response may be diminished by employing avariety of immunosuppressants, so as to permit repetitiveadministration, without a strong immune response. If packaged as anotherviral form, such as HSV, an amount to be administered is based onstandard knowledge about that particular virus (which is readilyobtainable from, for example, published literature) and can bedetermined empirically.

The present invention also provides host cells comprising (i.e.,transformed with) the adenoviral vectors described herein. Bothprokaryotic and eukaryotic host cells can be used as long as sequencesrequisite for maintenance in that host, such as appropriate replicationorigin(s), are present. For convenience, selectable markers are alsoprovided. Prokaryotic host cells include bacterial cells, for example,E. coli, B. subtilis, and mycobacteria. Among eukaryotic host cells areyeast, insect, avian, plant, C. elegans (nemotode) and mammalian.Examples of fungi (including yeast) host cells are S. cerevisiae,Kluyveromyces lactis (K. lactis), species of Candida including C.albicans and C. glabrata, Aspergillus nidulans, Schizosaccharomycespombe (S. pombe), Pichia pastoris, and Yarrowia lipolytica. Examples ofmammalian cells are COS cells, mouse L cells, LNCaP cells, Chinesehamster ovary (CHO) cells, human embryonic kidney (HEK) cells, andAfrican green monkey cells. Xenopus laevis oocytes, or other cells ofamphibian origin, may also be used. Host systems are known in the artand need not be described in detail herein. Suitable host cells alsoinclude any cells that produce AFP or any protein that is known toactivate an AFP-TRE (whether this protein is produced naturally orrecombinantly).

The present invention also includes compositions, includingpharmaceutical compositions, containing the adenoviral vectors describedherein. Such compositions are useful for administration in vivo, forexample, when measuring the degree of transduction and/or effectivenessof cell killing in an individual. Preferably, these compositions furthercomprise a pharmaceutically acceptable excipient. These compositions,which can comprise an effective amount of an adenoviral vector of thisinvention in a pharmaceutically acceptable excipient, are suitable forsystemic administration to individuals in unit dosage forms, sterileparenteral solutions or suspensions, sterile non-parenteral solutions ororal solutions or suspensions, oil in water or water in oil emulsionsand the like. Formulations for parenteral and nonparenteral drugdelivery are known in the art and are set forth in Remington'sPharmaceutical Sciences, 18th Edition, Mack Publishing (1990)Pharmaceutical compositions also include lyophilized and/orreconstituted forms of the adenoviral vectors (including those packagedas a virus, such as adenovirus) of the invention.

The present invention also encompasses kits containing an adenoviralvector(s) of this invention. These kits can be used for diagnosticand/or monitoring purposes, preferably monitoring. Procedures usingthese kits can be performed by clinical laboratories, experimentallaboratories, medical practitioners, or private individuals. Kitsembodied by this invention allow someone to detect the presence ofAFP-producing cells in a suitable biological sample, such as biopsyspecimens.

The kits of the invention comprise an adenoviral vector described hereinin suitable packaging. The kit may optionally provide additionalcomponents that are useful in the procedure, including, but not limitedto, buffers, developing reagents, labels, reacting surfaces, means fordetection, control samples, instructions, and interpretive information.

Preparation of the Adenovirus Vectors of the Invention

The adenovirus vectors of this invention can be prepared usingrecombinant techniques that are standard in the art. Generally, anAFP-TRE is inserted 5′ to the adenoviral gene of interest, preferablyone or more early genes (although late gene(s) may be used). An AFP-TREcan be prepared using oligonucleotide synthesis (if the sequence isknown) or recombinant methods (such as PCR and/or restriction enzymes).Convenient restriction sites, either in the natural adeno-DNA sequenceor introduced by methods such as oligonucleotide directed mutagenesisand PCR, provide an insertion site for an AFP-TRE. Accordingly,convenient restriction sites for annealing (i.e., inserting) an AFP-TREcan be engineered onto the 5′ and 3′ ends of an AFP-TRE using standardrecombinant methods, such as PCR.

Polynucleotides used for making adenoviral vectors of this invention maybe obtained using standard methods in the art, such as chemicalsynthesis, by recombinant methods, and/or by obtaining the desiredsequence(s) from biological sources.

Adenoviral vectors are conveniently prepared by employing two plasmids,one plasmid providing for the left hand region of adenovirus and theother plasmid providing for the right hand region, where the twoplasmids share at least about 500 nt of middle region for homologousrecombination. In this way, each plasmid, as desired, may beindependently manipulated, followed by cotransfection in a competenthost, providing complementing genes as appropriate, or the appropriatetranscription factors for initiation of transcription from a CEA-TRE forpropagation of the adenovirus. Plasmids are generally introduced into asuitable host cell such as 293 cells using appropriate means oftransduction, such as cationic liposomes. Alternatively, in vitroligation of the right and left-hand portions of the adenovirus genomecan also be used to construct recombinant adenovirus derivativecontaining all the replication-essential portions of adenovirus genome.Berkner et al. (1983) Nucleic Acid Research 11: 6003-6020; Bridge et al.(1989) J. Virol. 63: 631-638.

For convenience, plasmids are available that provide the necessaryportions of adenovirus. Plasmid pXC.1 (McKinnon (1982) Gene 19:33-42)contains the wild-type left-hand end of Ad5. pBHG10 (Bett et al. (1994)Proc. Natl. Acad. Sci USA 91:8802-8806; Microbix Biosystems Inc.,Toronto) provides the right-hand end of Ad5, with a deletion in E3. Thedeletion in E3 provides room in the virus to insert a 3 kb AFP-TREwithout deleting the endogenous enhancer/promoter. Bett et al. (1994).The gene for E3 is located on the opposite strand from E4 (r-strand).pBHG11 provides an even larger E3 deletion (an additional 0.3 kb isdeleted). Bett et al. (1994).

For manipulation of the early genes, the transcription start site of Ad5E1A is at 498 and the ATG start site of the E1A protein is at 560 in thevirus genome. This region can be used for insertion of an AFP-TRE. Arestriction site may be introduced by employing polymerase chainreaction (PCR), where the primer that is employed may be limited to theAd5 genome, or may involve a portion of the plasmid carrying the Ad5genomic DNA. For example, where pBR322 is used, the primers may use theEcoRI site in the pBR322 backbone and the XbaI site at 1339 of Ad5. Bycarrying out the PCR in two steps, where overlapping primers at thecenter of the region introduce a 30 sequence change resulting in aunique restriction site, one can provide for insertion of AFP-TRE atthat site. Example 1 provides a more detailed description of anadenoviral vector in which E1A is under AFP-TRE control.

A similar strategy may also be used for insertion of an AFP-TRE toregulate E1B. The E1B promoter of Ad5 consists of a single high-affinityrecognition site for Spl and a TATA box. This region extends from 1636to 1701. By insertion of an AFP-TRE in this region, one can provide forcell-specific transcription of the E1B gene. By employing the left-handregion modified with an AFP-TRE regulating E1A as the template forintroducing an AFP-TRE to regulate E1B, the resulting adenovirus vectorwill be dependent upon the cell-specific transcription factors forexpression of both E1A and E1B. Example 1 provides a more detaileddescription of how such constructs can be prepared.

Similarly, an AFP-TRE can be inserted upstream of the E2 gene to makeits expression cell-specific. The E2 early promoter, mapping in Ad5 from27050-27150, consists of a major and a minor transcription initiationsite, the latter accounting for about 5% of the E2 transcripts, twonon-canonical TATA boxes, two E2F transcription factor binding sites andan ATF transcription factor binding site. For a detailed review of theE2 promoter architecture see Swaminathan et al., Curr. Topics in Micro.and Imm. (1995) 199 (part 3):177-194.

The E2 late promoter overlaps with the coding sequences of a geneencoded by the counterstrand and is therefore not amenable to geneticmanipulation. However, the E2 early promoter overlaps only for a fewbase pairs with sequences coding for a 33-kDa protein on thecounterstrand. Notably, the SpeI restriction site (Ad5 position 27082)is part of the stop codon for the above mentioned 33 kDa protein andconveniently separates the major E2 early transcription initiation siteand TATA-binding protein site from the upstream transcription factorbinding sites E2F and ATF. Therefore, insertion of a PB-TRE having SpeIends into the SpeI site in the 1-strand would disrupt the endogenous E2early promoter of Ad5 and should allow AR-restricted expression of E2transcripts.

For E4, one must use the right hand portion of the adenovirus genome.The E4 transcription start site is predominantly at 35609, the TATA boxat 35638 and the first ATG/CTG of ORF 1 is at 35532. Virtanen et al.(1984) J. Virol. 51: 822-831. Using any of the above strategies for theother genes, an AFP-TRE may be introduced upstream from thetranscription start site. For the construction of mutants in the E4region, the co-transfection and homologous recombination are performedin W162 cells (Weinberg et al. (1983) Proc. Natl. Acad. Sci.80:5383-5386) which provide E4 proteins in trans to complement defectsin synthesis of these proteins. Alternatively, these constructs can beproduced by in vitro ligation.

Preparation of ADP-containing adenoviral vectors follows principlesoutlined above and known in the art. If the ADP encoding sequence is tobe introduced, it may be inserted recombinantly using methods such asthose described in Examples 5 and 6. Alternatively, an adenoviral vectoralready containing an ADP encoding sequence may be used to construct arecombinant vector containing other added and/or manipulated elements,such as a TRE or transgene.

Methods of packaging adenovirus polynucleotides into adenovirusparticles are known in the art and are described in the Examples.

Methods Using the Adenovirus Vectors of the Invention

The subject vectors can be used for a wide variety of purposes, whichwill vary with the desired or intended result. Accordingly, the presentinvention includes methods using the adenoviral vectors described above.

In one embodiment, methods are provided for conferring selectivecytoxicity in cells which allow an AFP-TRE to function (i.e., a targetcell), preferably cells expressing AFP comprising contacting the cellswith an adenovirus vector described herein. Cytotoxicity can be measuredusing standard assays in the art, such as dye exclusion, ³H-thymidineincorporation, and/or lysis.

In another embodiment, methods are provided for propagating anadenovirus specific for cells which allow an AFP-TRE to function,preferably mammalian cells expressing AFP. These methods entailcombining an adenovirus vector with the cells, whereby said adenovirusis propagated.

Another embodiment provides methods of killing cells which allow anAFP-TRE to function, such as cells expressing AFP, in a mixture ofcells, comprising combining the mixture of cells with an adenovirusvector of the present invention. The mixture of cells is generally amixture of normal cells and cancerous cells producing androgen receptor,and can be an in vivo mixture or in vitro mixture.

The invention also includes methods for detecting cells which allow anAFP-TRE to function, such as cells expressing AFP, in a biologicalsample. These methods are particularly useful for monitoring theclinical and/or physiological condition of an individual (i.e., mammal),whether in an experimental or clinical setting. For these methods, cellsof a biological sample are contacted with an adenovirus vector, andreplication of the adenoviral vector is detected. Alternatively, thesample can be contacted with an adenovirus in which a reporter gene isunder control of an AFP-TRE. Expression of the reporter gene indicatesthe presence of cells that allow an AFP-TRE to function, such asAFP-producing cells. Alternatively, an adenovirus can be constructed inwhich a gene conditionally required for cell survival is placed undercontrol of an AFP-TRE. This gene may encode, for example, antibioticresistance. The adenovirus is introduced into the biological sample, andlater the sample is treated with an antibiotic. The presence ofsurviving cells expressing antibiotic resistance indicates the presenceof cells which allow an AFP-TRE to function, such as cells producing (orcapable of producing) AFP. A suitable biological sample is one in whichAFP-producing cells may be or are suspected to be present. Generally, inmammals, a suitable clinical sample is one in which cancerous cellsproducing AFP, such as hepatocellular carcinoma cells, are suspected tobe present. Such cells can be obtained, for example, by needle biopsy orother surgical procedure. Cells to be contacted may be treated topromote assay conditions, such as selective enrichment, and/orsolubilization. In these methods, AFP-producing cells can be detectedusing in vitro assays that detect adenoviral proliferation, which arestandard in the art. Examples of such standard assays include, but arenot limited to, burst assays (which measure virus yield) and plaqueassays (which measure infectious particles per cell). Propagation canalso be detected by measuring specific adenoviral DNA-replication, whichare also standard assays.

The invention also provides methods of modifying the genotype of atarget cell, comprising contacting the target cell with an adenovirusvector described herein, wherein the adenoviral vector enters the cell.

The invention further provides methods of suppressing tumor cell growth,preferably a tumor cell that expresses AFP, comprising contacting atumor cell with an adenoviral vector of the invention such that theadenoviral vector enters the tumor cell and exhibits selectivecytotoxicity for the tumor cell. Tumor cell growth can be assessed byany means known in the art, including, but not limited to, measuringtumor size, determining whether tumor cells are proliferating using a³H-thymidine incorporation assay, or counting tumor cells. “Suppressing”tumor cell growth means any or all of the following states: slowing,delaying, and stopping tumor growth, as well as tumor shrinkage.“Suppressing” tumor growth indicates a growth state that is curtailedwhen compared to growth without contact with, i.e., transfection by, anadenoviral vector described herein.

The invention also provides methods of lowering the levels of a tumorcell marker in an individual, comprising administering to the individualan adenoviral vector of the present invention, wherein the adenoviralvector is selectively cytotoxic toward cells producing the tumor cellmarker. Tumor cell markers include, but are not limited to, AFP, PSA,hK2, and carcinoembryonic antigen. Methods of measuring the levels of atumor cell marker are known to those of ordinary skill in the art andinclude, but are not limited to, immunological assays, such asenzyme-linked immunosorbent assay (ELISA), using antibodies specific forthe tumor cell marker. In general, a biological sample is obtained fromthe individual to be tested, and a suitable assay, such as an ELISA, isperformed on the biological sample.

The invention also provides methods of treatment, in which an effectiveamount of an adenoviral vector(s) described herein is administered to anindividual. Treatment using an adenoviral vector(s) is indicated inindividuals with tumors such as hepatocellularcarcinoma. Also indicatedare individuals who are considered to be at risk for developingAFP-associated diseases (including cancer), such as those who have had afamily history of the disease(s), and/or have had disease that has beenresected or treated in some other fashion, such as chemotherapy.Determination of suitability of administering adenoviral vector(s) ofthe invention will depend, inter alia, on assessable clinical parameterssuch as serological indications and histological examination of tissuebiopsies. Generally, a pharmaceutical composition comprising anadenoviral vector(s) is administered. Pharmaceutical compositions aredescribed above.

The amount of adenoviral vector(s)to be administered will depend onseveral factors, such as route of administration, the condition of theindividual, the degree of aggressiveness of the disease, the particularPB-TRE employed, and the particular vector construct (i.e., whichadenovirus gene(s) is under PB-TRE control).

If administered as a packaged adenovirus, from about 10⁴ to about 10¹⁴,preferably from about 10⁴ to about 10¹², more preferably from about 10⁴to about 10¹⁰. If administered as a polynucleotide construct (i.e., notpackaged as a virus), about 0.01 μg to about 100 μg can be administered,preferably 0.1 μg to about 500 μg, more preferably about 0.5 μg to about200 μg. More than one adenoviral vector can be administered, eithersimultaneously or sequentially. Administrations are typically givenperiodically, while monitoring any response. Administration can begiven, for example, intratumorally, intravenously or intraperitoneally.

The adenoviral vectors of the invention can be used alone or inconjunction with other active agents, such as chemotherapeutics, thatpromote the desired objective.

The following examples are provided to illustrate but not limit theinvention.

EXAMPLES Example 1 Adenovirus Vectors Containing an AFP-TRE DrivingTranscription of E1A and/or E1B

A human embryonic kidney cell line, 293, efficiently expresses E1A andE1B genes of Ad5 and exhibits a high transfection efficiency withadenovirus DNA. For these experiments, 293 cells were co-transfectedwith one left end Ad5 plasmid and one right end Ad5 plasmid. Homologousrecombination generates adenoviruses with the required genetic elementsfor replication in 293 cells which provide E1A and E1B proteins in transto complement defects in synthesis of these proteins.

The plasmids to be combined were co-transfected into 293 cells usingcationic liposomes such as Lipofectin (DOTMA:DOPE™, Life Technologies)by combining the two plasmids, then mixing the plasmid DNA solution (10μg of each plasmid in 500 μl of minimum essential medium (MEM) withoutserum or other additives) with a four-fold molar excess of liposomes in200 μl of the same buffer. The DNA-lipid complexes were then placed onthe cells and incubated at 37° C., 5% CO₂ for 16 hours. After incubationthe medium was changed to MEM with 10% fetal bovine serum and the cellsare further incubated at 37° C., 5% CO₂, for 10 days with-two changes ofmedium. At the end of this time the cells and medium were transferred totubes, freeze-thawed three times, and the lysate was used to infect 293cells at the proper dilution to detect individual viruses as plaques.

Plaques obtained were plaque purified twice, and viruses werecharacterized for presence of desired sequences by PCR and occasionallyby DNA sequencing. For further experimentation, the viruses werepurified on a large scale by cesium chloride gradient centrifugation.

Using the above procedure, three replication competent, hepatocarcinomacell-specific adenoviruses were produced: CN732, which contains anAFP-TRE driving the expression of the E1A gene; CN733, which containstwo AFP-TREs driving expression of the E1A and E1B genes; and CN734,which contains an AFP-TRE driving E1B expression. The viruses weregenerated by homologous recombination in 293 cells and cloned twice byplaque purification. The structure of the genomic DNA was analyzed byPCR and sequencing of the junctions between the inserted sequences andthe Ad genomic sequences to confirm that the viruses contained thedesired structures. The structure of the viruses was also confirmed bySouthern blot.

TABLE 1 Adenovirus vectors containing AFP-TRE Virus Name Left EndPlasmid Right End Plasmid E1A-AFP CN732 CN219 BHG10 E1A/E1B-AFP CN733CN224 BHG10 EIB-AFP CN734 CN234 BHG10

Virus Construction

Plasmid pXC.1 was purchased from Microbix Biosystems Inc. (Toronto).pXC.1 contains Ad5 sequences from (nucleotide) 22 to 5790. We introducedan AgeI site 12 bp 5′ to the E1A initiation codon (Ad5 547) byoligo-directed mutagenesis and linked PCR. To achieve this, pXC.1 wasPCR amplified using primers:

5′-TCGTCTTCAAGAATTCTCA (15.133A) (SEQ ID NO: 3), containing an EcoRIsite, and

5′-TTTCAGTCACCGGTGTCGGA (15.134B) (SEQ ID NO: 4), containing an extra Ato introduce an AgeI site. This created a segment from the EcoRI site inthe pBR322 backbone to Ad5 560. A second segment of pXC.1 from Ad 541 tothe XbaI site at Ad nucleotide 1339 was amplified using primers:

5′-GCATTCTCTAGACACAGGTG (15.133B) (SEQ ID NO: 5) containing an XbaIsite, and

5′-TCCGACACCGGTGACTGAAA (15.134A) (SEQ ID NO: 6), containing an extra Tto introduce an AgeI site. A mixture of these two PCR amplified DNAsegments was mixed and amplified with primers 15.133A and 15.133B tocreate a DNA segment from the EcoRI site to the XbaI site of pXC.1. ThisDNA segment encompasses the leftmost 1317 bases of Ad sequence andcontains an AgeI site at Ad 547. This DNA segment was used to replacethe corresponding segment of pXC. 1 to create CN95.

An EagI site was created upstream of the E1B start site by inserting a Gresidue at Ad5 1682 by oligonucleotide directed mutagenesis as above. Tosimplify insertion of an AFP-TRE in the EagI site the endogenous EagIsite in CN95 was removed by digestion with EagI, treatment with mungbean nuclease, and re-ligation to construct CN114. The primers:

5′-TCGTCTTCAAGAATTCTCA (15.133A) (SEQ ID NO: 3), containing an EcoRIsite, and

5′-GCCCACGGCCGCATTATATAC (9.4) (SEQ ID NO: 7), containing an EagI site,and

5′-GTATATAATGCGGCCGTGGGC (9.3) (SEQ ID NO: 8) containing an extra G andan EagI site, and

5′-CCAGAAAATCCAGCAGGTACC (24.020) (SEQ ID NO: 9), containing a KpnIsite, were used to amplify the segment between 1682 and the KpnI site atAd5 2048. Co-amplification of the two segments with primers 15.133A and24.020 yielded a fragment with an EagI site at Ad5 1682 which was usedto replace the corresponding EcoRI/KpnI site in pXC.1 to constructCN124.

For construction of CN732, human AFP enhancer domains A and B (includedin the region −3954 bp to −3335 bp relative to the AFP cap site) werePCR amplified from human genomic DNA (Clontec, Palo Alto, Calif.) usingthe following primers:

5 ′GTGACCGGTGCATTGCTGTGAACTCTGTA 3′ (39.055B) (SEQ ID NO: 10)

5′ATAAGTGGCCTGGATAAAGCTGAGTGG 3′ (39.044D) (SEQ ID NO: 11)

The AFP promoter was amplified from −163 to +34 using the followingprimers:

5′ GTCACCGGTCTTTGTTATTGGCAGTGGT 3′ (39.055J) (SEQ ID NO: 12)

5′ ATCCAGGCCACTTATGAGCTCTGTGTCCTT 3′ (29.055M) (SEQ ID NO: 13)

The enhancer and promoter segments were annealed, and a fusion constructwas generated using overlap PCR with primers 39.055B and 39.055J. Thisminimal enhancer/promoter fragment was digested with PinA1 and ligatedwith CN124 using the engineered AgeI site 5′ of the E1A cap site toproduce CN219. The liver specific viral vector CN732 was generated byhomologous recombination by cotransfecting 293 cells with CN219 andBHG10.

CN733 was constructed by using the following two PCR primers to amplifythe enhancer/promoter element described above (−3954 to −3335 and −174to +29):

5′ TATCGGCCGGCATTGCTGTGAACTCT 3′ (39.077A) (SEQ ID NO: 14)

5′ TTACGGCCGCTTTGTTATTGGCAGTG 3′ (39.077C) (SEQ ID NO: 15)

The PCR product was digested with EagI and ligated into similarly cutCN219. The resulting plasmid, CN224, contains two identical AFPregulatory elements, one each modulating expression of the E1A gene andthe E1B gene. CN733 was generated by homologous recombination in 293cells by cotransfecting CN224 and BHG10.

To make CN734, the AFP-TRE regulating the expression of the E1A gene wasexcised from CN224 by digesting the plasmid with PinA1 and religatingthe vector. The resulting plasmid, CN234, was co-transfected with BHG10in 293 cells to generate CN734.

Virus Growth in Vitro

Growth selectivity of CN732, CN733, and CN734 was analyzed in plaqueassays in which a single infectious particle produces a visible plaqueby multiple rounds of infection and replication. Virus stocks werediluted to equal pfu/ml, then used to infect monolayers of cells for 1hour. The inoculum was then removed and the cells were overlayed withsemisolid agar containing medium and incubated at 37° C. for 10 days (12days for Table 4). Plaques in the monolayer were then counted and titersof infectious virus on the various cells were calculated. The data werenormalized to the titer of CN702 (wild type) on 293 cells. The resultsof four representative assays are shown in Tables 2-5.

TABLE 2 Plaque assay for 733 (E1A/E1B) Cell line Virus Titer Avg. titreTitre/293 702/733 293 733 2.70 × 10⁶ 2.65 × 10⁶ 1 N/A (control) 733 2.60× 10⁶ 702 1.30 × 10⁶ 1.70 × 10⁶ 1 702 2.10 × 10⁶ Hep3B 733 1.01 × 10⁷1.02 × 10⁷ 3.7 .37 (AFP⁺) 733 1.03 × 10⁷ 702 1.00 × 10⁶ 7.02 × 10⁵ 1.36702 5.00 × 10⁵ HepG2 733 9.70 × 10⁶ 1.04 × 10⁷ 3.92 0.292 (AFP⁺) 7331.10 × 10⁷ 702 1.60 × 10⁶ 1.95 × 10⁶ 1.14 702 2.30 × 10⁶ LNCaP 733 4.00× 10³ 3.00 × 10³ 0.0011 290 (AFP⁻) 733 2.00 × 10³ 702 4.00 × 10⁵ 5.05 ×10⁵ 0.32 702 7.00 × 10⁵ HBL100 733 0 0 0 100-1000 (AFP⁻) 733 0 702 1.00× 10² 3.07 × 10² 0.00022 702 6.40 × 10²

TABLE 3 CN732, CN733, CN734 Plaque Assay Data Cell line Virus Ave TitreTitre/293 7XX/702 293 702  1.2 × 10⁶ 1 (control) 732 6.15 × 10⁵ 1 7332.20 × 10⁶ 1 734 2.50 × 10⁵ 1 Huh-7 702 1.10 × 10⁴ 0.01375 732 1.10 ×10⁵ 0.1788 13 733 8.50 × 10⁴ 0.0386 3 734 1.90 × 10⁴ 0.076 6 Sk-Hep-1702 9.00 × 10² 0.00113 732 0   0 0 733 0   0 0 734 1.00 × 10³ 0.004 4HeLa 702 2.45 × 10² 0.00030625 732 0   0 0 733 1.5 6.81 × 10⁻⁷ 0.0022734 2.50 × 10¹ 0.01 32 MCF-7 702 3.10 × 10³ 0.003875 732 7.5 1.22 × 10⁻⁵0.0031 733 2.30 × 10¹ 1.05 × 10⁻⁵ 0.0027 734 1.70 × 10³ 0.0068 2 DLD-1702 1.70 × 10³ 0.00213 732 1.40 × 10¹ 2.28 × 10⁻⁵ 0.011 733 1   4.54 ×10⁻⁷ 0.00021 734 1.55 × 10³ 0.0062 3

TABLE 4 CN732, CN733, CN734 Plaquing Efficiency Cell line Virus Titre293 702 1 × 10⁷ 732 1 × 10⁷ 733 1 × 10⁷ 734 1 × 10⁷ HepG2 702 5 × 10⁶(AFP⁺) 732 3 × 10⁶ 733 3 × 10⁶ 734 1 × 10⁷ Sk-Hep-1 702 6 × 10⁴ (AFP⁻)732 0 733 0 734 3 × 10⁴ OVCAR-3 702 8 × 10⁵ (AFP⁻) 732 0 733 0 734 3 ×10⁴ HBL-100 702 2 × 10⁶ (AFP⁻) 732 0 733 0 734 1 × 10⁴

TABLE 5 Plaque assay for CN732, CN733, and CN734 Titre (cell line)/ Cellline Virus Ave Titre Titer 293 CN7XX/CN702 293 702 5.0 × 10⁶ 1 (control)732 4.8 × 10⁶ 1 733 3.2 × 10⁶ 1 734 3.0 × 10⁸ 1 HepG2 702 2.3 × 10⁷ 4.6— (AFP⁺) 732 3.2 × 10⁷ 6.7 1.5 733 6.0 × 10⁶ 1.9 0.41 734 4.2 × 10⁸ 1.40.30 DU145 702 2.2 × 10⁶ 0.44 — (AFP⁻) 732 3.0 × 10⁴ 0.0063 0.0143 7333.1 × 10³ 0.00097 0.002 734 1.0 × 10⁷ 0.033 0.075 HBL-100 702 4.0 × 10⁵0.8 — (AFP⁻) 732 0 — 0 733 0 — 0 734 6.0 × 10⁶ 0.02 0.025 OVCAR-3 7023.3 × 10⁵ 0.066 — (AFP⁻) 732 0 — 0 733 0 — 0 734 3.1 × 10⁵ 0.001 0.015

The wild type virus CN702 produced plaques on each of the cell linestested. The number of plaques produced by CN702 was used as a base lineagainst which to compare plaque formation by CN733.

In 293 cells growth of the viruses should be independent of thealterations to the E1 region due to the trans complimentation in thiscell line. As expected, both CN702 and CN733 produced similar numbers ofplaques on 293 cells.

Regarding the data from Table 1, in the AFP positive cell lines Hep3Band HepG2 CN702 produced similar numbers of plaques relative to 293cells. In contrast CN733 produced approximately four fold more plaquesin the AFP positive cell lines than in 293 cells. The super normal levelof plaque formation by CN733 in the AFP positive lines indicates thatthe AFP enhancer is active in these cells.

In the AFP negative cell lines LNCaP and HBL100 growth of both viruseswas curtailed but to different extents. Wild type CN702 virus producedplaques in LNCaP cells at approximately 30% of the level seen in 293cells. In HBL-100 cells CN702 formed plaques at 0.02% of the levelformed in 293 cells. CN733 plaque formation was diminished even furtherin these AFP negative cell lines relative to CN702. In LNCaP cells CN733produced plaques at a level 0.1% of that seen in 293 cells. In HBL100cells CN733 did not produce plaques at all. In comparison to CN702, thegrowth of CN733 on AFP negative cell lines was reduced by at least 100fold. This compares favorably with previous results where the E1Bpromoter of Ad40 was shown to specify a differential of approximately100 fold between gut and conjunctival epithelial tissues (Bailey et al.,1994) and with deletion mutants of the E1b gene which were shown tospecify a 100 fold differential in Ad growth between p53+ and p53− cells(Bischoff et al., 1996). Lastly, comparison of the titer of an AFP+ celltype to the titer of an AFP− cell type provides a key indication thatthe, overall replication preference is enhanced due to depressedreplication in AFP− cells as well as the replication in AFP+ cells.

Regarding the data from Table 3, several observations can be made.First, CN732, CN733, and CN734 all plaque as efficiently in Huh-7 cellsas CN702. In contrast, the plaquing efficiency for two of theadenoviruses (CN732 and CN733) decreases dramatically in the non-AFPproducing cell lines included in the experiment. In the non AFPproducing hepatocellular carcinoma cell line Sk-Hep-1, CN732 and CN733produced no plaques at the dilutions tested. The results are similar forthese two viruses in Hela, MCF-7, and DLD-1. CN702's efficiency in DLD-1cells exceeds CN733's by over 4000 fold.

With respect to the data in Table 4 (in which titers are normalized to1×10⁷ in 293 cells), CN732, CN733, and CN734 plaqued similarly to wildtype (CN702) in HepG2 cells. However, these viruses plaqued poorlycompared to CN702 in cell lines that do not express AFP. CN732 and CN733produced no plaques at the dilutions tested in SK-Hep-1, OVCAR-3 andHBL-100, thus displaying significant titer differential. Thiscorresponds to at least a 10,000 fold difference with wild type inHBL-100 and OVCAR-3 and a 1,000 fold difference in SK-Hep-1. CN734 alsoplaqued less efficiently than CN702 in OVCAR-3 (25 fold) and HBL-100(200 fold) cells.

The data of Table 5 suggest that CN732, CN733, and CN734 plaque asefficiently as CN702 in cells that express AFP. However, they do notplaque as efficiently as CN702 in cell lines that do not express AFP.For example, neither CN732 nor CN733 produced any plaques at thedilutions tested in HBL100 cells or OVCAR-3 cells. CN734's plaquingdifferential was not as striking as CN732's or CN733's in the cell linestested. It plaqued 13-fold, 40-fold, and 67-fold less efficiently thanwild type in DU145, HBL100, and OVCAR-3, respectively.

The plaque assay data demonstrate that human adenovirus can be modifiedusing an AFP-TRE to develop viruses with selective growth properties forAFP producing cells, particularly AFP-producing tumor cells such ashepatic carcinoma cells.

Western Analysis of EIA Expression

In the next experiment, we examined the effect of an AFP-TRE on theaccumulation of E1A protein in CN733 infected cells. We reasoned that ifone of the AFP regulatory regions installed in CN733 was modulating theE1A gene, the level of E1A protein in infected cells should also beaffected. A western blot was conducted to test our hypothesis.

CN733's E1A accumulation was evaluated in Huh-7, SK-Hep-1 and DLD-1cells. Monolayers were infected with either CN702 or CN733 at an MOI often and the harvested at various time points after infection. Sampleswere electrophoresed through a 10% acrylimide gel and transferred byelectrophoresis to a nitrocellulose membrane. E1A protein was detectedby using the ECL Western Detection system (Amersham, Arlington Heights,Ill.) using the suggested protocol. The primary antibody used was rabbitanti-Ad2 E1A antibody (Santa Cruz Biotechnology, Santa Cruz, Calif.).The results are shown in FIG. 6(A).

E1A accumulated rapidly in CN702 and CN733 infected Huh-7 cells. A highlevel of E1A was also detected in CN702 infected Dld-1 cells. However,little E1A protein was detected in CN733 infected Dld-1 cells. Thisresult is intriguing because it suggests that CN733's poor plaquingefficiency in non AFP producing cell lines could be attributed to itsrestricted E1A expression. These data are consistent with the hypothesisthat the AFP-TRE affects CN733's compromised replication innon-permissive cell types.

The experiment was repeated using Sk-Hep-1 cells as non AFP producingcells. Data were obtained after 24 hours post-infection. The results areshown in FIG. 6(B). The conclusion of this experiment is the same as theprevious experiment: E1A expression is tightly regulated by the AFP-TRE.

Growth of CN733

CN733's growth in AFP and non AFP producing cells was evaluated.Monolayers of Huh-7, Sk-Hep-1, and Dld-1 cells were infected at an MOIof ten with either CN702 or CN733. At various times after infection,duplicate samples were harvested, freeze-thawed three times, and titeredon 293 cells to determine the total virus yield. Virus yield curves forCN702 and CN733 are plotted in FIGS. 7(A)-(C).

CN702 and CN733 grew efficiently in Huh-7 cells. Huh-7 cells producedsimilar amounts of infectious CN702 and CN733. In contrast, CN733'sgrowth was severely restricted in SK-Hep-1 cells. CN702's titer at theconclusion of the experiment is about 1000 times greater than CN733'stiter. The results were similar in Dld-1 cells.

The growth experiment was also performed to compare growth of CN732,CN733, and CN734 in HepG2 cells. Monolayers of HepG2 cells were infectedat a multiplicity of infection (MOI) of two and harvested at varioustimes after infection. Samples were titered on 293 cells to determinethe final virus yield. The results are shown in in FIGS. 8(A)-(C). Thedata demonstrate that the adenovirus containing AFP-TREs growefficiently in this cancer cell line. CN732, CN733, and CN734 each reacha high final titer at 36 hours post infection that is similar to that ofCN702.

In another experiment, propagation was evaluated in primary hepatocytes(hNheps) isolated from a donor (32 year old black male) three daysbefore the start of the experiment. Monolayers of cells were infectedwith virus at an MOI of two, harvested at various times after infectionand titered on 293 monolayers. The results are shown in FIGS. 9(A)-(C).The data suggest that CN732 and CN733 grow less efficiently in hNhepsthan CN702. CN732's growth is delayed by twenty-four hours compared toCN702's. At thirty-six hours post infection, there is over ten fold moreinfectious CN702 than CN733. CN733's growth is delayed by thirty-sixhours. At thirty-six hours post infection, there is nearly 1000 timesmore infections CN702 than CN733. CN734 grows similarly to CN702. Thedata also suggest that CN733 has the most restrictive phenotype,followed by CN732 and CN734. Taken together, these results also indicatethat an AFP-TRE inserted upstream of the E1A gene may be more effectivein restricting host-range than an AFP-TRE engineered upstream of the E1Bregion. The presence of two AFP-TREs is even more effective.

In conclusion, the experiments described above indicate that it ispossible to restrict an adenoviral vector's host range to AFP producingcells. As demonstrated by plaque assay and growth assay, the adenovirusvectors containing an AFP-TRE propagate efficiently in HepG2 and Huh-7cells but poorly in non AFP producing cells.

Example 2 Transient Expression Assay with Plasmid CN236

The ability of the 800 bp AFP-TRE in CN236 to drive expression ofluciferase gene was determined in a transient expression assay. Changliver cells, which do not make AFP and Hep3B cells, which produce AFP,were transformed with CN236 or pGL2Luc using the cationic lipids (i.e.,lipofectin) method. pGL2-Basic (Promega) is a construct that does notcontain the AFP regulatory gene only the backbone the gene was insertedinto, hence it is the negative control construct for the assay. Theplasmid vector, pGL2-Luc (Promega) served as a positive control. Cellswere cultured in DMEM supplemented with 10% fetal calf serum (FCS) and,48 hours later, assayed for luciferase activity. Luciferase activity wasmeasured according to manufacturer's instructions in the kit (PackardInstruments) and quantitated using a luminometer. The results, shown inTable 6, below, are expressed in relative light units (RLUs).

TABLE 6 Negative Cell Line Control pGL2-Luc CN236 Hep3B 0.017 4.118 7549Chang Liver 0.29 2.94 7.0

These data indicate that the fragment of DNA is active in AFP positiveliver cells (Hep3B), but not AFP negative liver cells (Chang liver).

Example 3 Testing Cytotoxic Ability of Adenovirus Vectors on HuH7 TumorXenografts

An especially useful objective in the development of AFP-specificadenoviral vectors is to treat patients with AFP-producing tumors, suchas hepatocellular carcinoma. An initial indicator of the feasibility isto test the vector(s) for cytotoxic activity against HuH7 tumorxenografts grown subcutaneously in Balb/c nu/nu mice. Mice are givens.c. injections with 1×10⁷ HuH7 carcinoma cells in PBS. Tumor cells canbe tested for AFP production by assaying for AFP in serum using standardassays (for example, ELISA).

For this experiment, test adenovirus vectors are introduced into themice either by direct intratumoral, intravenous, or intraperitonealinjection of approximately 10⁸ pfu of virus (if administered as apackaged virus) in 0.1 ml PBS+10% glycerol or intravenously via the tailvein. If administered as a polynucleotide construct (i.e., not packagedinto virus), 0.1 μg to 100 μg or more can be administered. Tumor sizesare measured and, in some experiments, blood samples are taken weekly.The effect of intratumoral injection of the adenoviral vector (such asCN733) on tumor size and serum AFP levels is compared to sham treatment.

While it is highly possible that a therapeutic based on the virusesdescribed here would be given intralesionally (i.e., direct injection),it would also be desirable to determine if intravenous (IV)administration of adenovirus vector can affect tumor growth. If so, thenit is conceivable that the virus could be used to treat metastatic tumordeposits inaccessible to direct injection. For this experiment, groupsof three to five mice bearing HuH7 tumors are inoculated with 10⁸ pfu ofan adenoviral vector (such as CN733) by tail vein injection, or withbuffer used to carry the virus as a negative control. The effect of IVinjection of the adenoviral vector on tumor size and serum AFP levels iscompared to sham treatment.

Example 4 Testing Cytotoxic Ability of Adenovirus Vector CN733 on HepG2Tumor Xenographs

An HCC mouse xenograft model was used to evaluate CN733's potential as atherapeutic adenovirus for liver cancer. The AFP producing HCC cell lineHepG2 was injected subcutaneously on the right flanks of Balb/c nu/numice. After allowing several weeks for the tumors to take, each wastreated with an intratumoral injection of either 1.5×10¹¹ particles ofCN733 in PBS, glycerol or buffer alone. Eleven mice bearing HepG2 tumorswere treated, six with CN733 and five with buffer. Tumors were measuredweekly until the conclusion of the experiment. Tumor volume wascalculated by multiplying the tumor's length by the square of its widthand dividing the product by two. FIG. 10(A) is a graph of average tumorvolume for each treatment group vs. time.

In six weeks, HepG2 tumors challenged with buffer grew to over fivetimes their original size. In contrast, tumor growth in CN733 treatedmice was attenuated. One tumor even regressed to 3% of its maximumvolume. These data suggest that CN733 invaded the tumors and deliveredcytotoxicity.

In addition to monitoring tumor growth, we harvested serum samples andassayed AFP levels. The results are shown in FIG. 11. The data suggestthat serum AFP levels rises more slowly in mice receiving CN733 than incontrol mice receiving buffer.

In another experiment, antitumor activity of different administrativeregimens was compared for CN733. Animals were treated with a singleintramuoral administration of either buffer (n=8, volume=919 mm³) or1.5×10¹¹ particles of CN733 (n=8, volume 944 mm³). A third group ofanimals was treated with five consecutive daily doses of 1.5×10¹¹particles of CN733 (n=8, volume=867 mm³). Despite the large systemicvirus burden, the mice displayed no obvious signs of toxicity. Tumorswere measured weekly by external caliper for four weeks after injection.Animals from groups treated with a single dose of CN733 and buffer weresacrificed four weeks after treatment because of excessive tumor burden.All animals from the group treated with five doses of CN733 surviveduntil the conclusion of the study. Despite the large systemic virusburden, these animals showed no obvious signs of treatment relatedtoxicity. The results are shown in FIG. 10(B). On average, buffertreated tumors increased to three times their initial volume by fourweeks after treatment. Tumors treated with a single dose of CN733increased to nearly four times their initial volume. In contrast, tumorstreated with five doses of CN733 remained the same volume. Five out ofeight tumors (63%) responded to treatment. One animal had no palpabletumor at the end of the study.

Statistical analysis using the Students T-test suggests that there wasno significant difference at any time point between buffer treatedanimals and those treated with one dose of CN733 (p>0.5). However, therewas a significant difference between buffer treated animals and thosetreated with five doses of CN733 beginning at two weeks post injection(p=0.045) and continuing through four weeks (p=0.034).

The data suggest that CN733 exhibits significant antitumor activity inHepG2 nude mouse xenografts. CN733 administered daily for fiveconsecutive days at a dose of 1.5×10¹¹ particles can cause tumorregression in some animals. A single dose, however, is not sufficient tocause tumor killing.

In the first experiment, the tumors responded to a single dose of CN733but did not appear to respond in the second. The inventors note thatthere is often a variation in tumor phenotype (including growthcharacteristics and AFP expression) from experiment to experiment.

In conclusion, the in vivo experiments suggest that CN733 causessignificant tumor killing in large hepatoma xenografts. Five doses ofintratumorally adminstered virus induced regression in four out of eightanimals and cured one animal twenty-eight days after injection. Onaverage, buffer treated tumors tripled while CN733 treated tumorsremained the same.

Example 5 Construction of an Adenoviral Vector Containing the CodingRegion for the Adenovirus Death Protein (ADP)

In AFP-specific viral vector CN733 (described above in Example 1), adeletion had been created in the E3 region to accomodate the AFP-TRE inthe E1 region. The ADP coding sequence from Ad2 was reintroduced intothe E3 region of Ad5 as follows.

An ADP cassette was constructed using overlap PCR. The Y leader, animportant sequence for correct expression of some late genes, was PCRamplified using primers:

5′ GCCTTAATTAAAAGCAAACCTCACCTCCG . . . Ad2 28287bp (37.124.1) (SEQ IDNO: 16); and

5′ GTGGAACAAAAGGTGATTAAAAAATCCCAG . . . Ad2 28622bp (37.146.1) (SEQ IDNO: 17).

The ADP coding region was PCR amplified using primers

5′ CACCTTTTGTTCCACCGCTCTGCTTATTAC . . . Ad2 29195bp (37.124.3) (SEQ IDNO: 18) and

5′ GGCTTAATTAACTGTGAAAGGTGGGAGC . . . Ad2 29872bp (37.124.4) (SEQ ID NO:19).

The two fragments were annealed and the overlap product was PCRamplified using primers 37.124.1 and 37.124.4. The ends of the productwere polished with Klenow fragment and ligated to BamHI cut pGEM-72(+)(CN241; Promega, Madison, Wis.). The ADP cassette was excised bydigesting CN241 with Pac 1 restriction endonuclease and ligated with twovectors, CN247 andCN248 generating plasmids CN252 and CN270,respectively. CN247 contains a unique PacI site in the E3 region and wasconstructed as follows. A plasmid containing the full length Ad5 genome,TG3602 (Transgene, France), was digested with BamHI and religated toyield CN221. The backbone of this plasmid (outside of the Ad5 sequence)contained a PacI site that needed to be removed to enable furthermanipulations. This was effected by digesting CN221 with PacI andpolishing the ends with T4 DNA polymerase, resulting in CN246. CN246 wasdigested with AscI and AvrII (to remove intact E3 region). This fragmentwas replaced by a similarly cut fragment derived from BHG11. Theresulting plasmid, CN 247, contained a deleted E3 region and a PacI sitesuitable for insertion of the ADP cassette fragment (described above).Ligation of CN247 with the ADP cassette generated CN252.

CN248 (a construct that would allow introduction of an ADP cassette intoAd that also contains a deletion/substitution in the E4 region) was madeas follows. The E4 region was deleted by digesting CN108, a constructthat contains right hand end Ad5 sequence from the unique EcoRI site inthe E3 region (derived from BHG10), with AvrII and AfIII. The only E4ORF necessary for viral replication, ORF 6, was reintroduced by PCRamplifying the ORF with primers,

33.81.1 (Ad5 33096):

GCAGCTCACTTAAGTTCATGTCG (SEQ ID NO: 20)

33.81.2 (Ad5 34084):

TCAGCCTAGGAAATATGACTACGTCCG (SEQ ID NO: 21)

The resulting plasmid is CN203. CN203 was digested with EcoRI andligated to CN209, a shuttle plasmid, to generate CN208. In the finalcloning step, CN208 was digested with AscI and AvrII and ligated tosimilarly cut E4 deletion/substitution with the ADP cassette.

Both CN252 and CN270 contain an E3 deletion. In addition, CN270 lackssome sequence in the E4 region as previously described. Adenoviralvectors are obtained via in vitro ligation of (1) appropriately preparedviral DNA digested with BamHI and (2) CN252 or CN257 also digested withBamHI. The ligation product is used to transfect 293 cells. Plaqueassays are performed as described in Example 1.

Example 6 Characterization of an E3 Deleted Adenovirus, CN751, thatContains the Adenovirus Death Protein Gene

An adenovirus death protein mutant, CN751, was constructed to testwhether such a construct may be more effective for cytotoxicity. Theadenovirus death protein (ADP), an 11.6 kD Asn-glycosylated integralmembrane peptide expressed at high levels late in infection, migrates tothe nuclear membrane of infected cells and affects efficient lysis ofthe host. The Adenovirus 5 (Ad5) E3 region expresses the adp gene.

Construction of CN751

CN751 was constructed in two parts. First, an E3 deleted platformplasmid that contains Ad5 sequence 3′ from the BamHI site at 21562bp wasgenerated. The Ad2 adp was engineered into the remainder of the E3region of this plasmid to yield CN252 (this cloning has been previouslydescribed). To construct the second part, the 5′ Ad5 sequence necessaryfor CN751 was obtained by digesting purified CN702 DNA with EcoRI andisolating the left hand fragment by gel extraction. After digestingCN252 with EcoRI, the left hand fragment of CN702 and CN252 wereligated. 293 cells were transfected with this ligation mixture bylipofection transfection and incubated at 37° C. Ten days later, thecells were harvested, freeze-thawed three times, and the supernatant wasplaqued on 293 monolayers. Individual plaques were picked and used toinfect monolayers of 293 cells to grow enough virus to test. Afterseveral days, plate lysates were screened using a polymerase chainreaction (PCR) based assay to detect candidate viruses. One of theplaques that scored positive was designated CN751.

Structural Characterization of CN751

The structure of CN751 was confirmed by two methods. First, primers37.124.1 (5′ GCCTTAATTAAAAGCAAACCTCACCTCCG Ad2 28287bp; SEQ ID NO: 16)and 37.124.4 (5′ GGCTTAATTAACTGTGAAAGGTGGGCTGC Ad2 29872bp; SEQ ID NO:19) were used to screen candidate viruses by PCR to detect the presenceof the adp cassette. CN751 produced an extension fragment consistentwith the expected product (1065bp). Second, CN751 was analyzed bySouthern blot. Viral DNA was purified, digested with PacI, SacI, andAccI/XhoI, and probed with a sequence homologous to the ADP codingregion. The structure of CN751 matched the expected pattern.

In Vitro Characterization of CN751

Two experiments were conducted to examine the cytotoxicity and virusyield of CN751. In the first study, CN751's cytotoxicity was evaluatedin LNCaP cells by measuring the accumulation of a cytosolic enzyme,lactate dehydrogenase (LDH), in the supernatant over several days. Thelevel of extracellular LDH correlates with the extent of cell lysis.Healthy cells release very little, if any, enzyme, whereas dead cellsrelease large quantities. LDH was chosen as a marker because it is astable protein that can be readily detected by a simple protocol.CN751's ability to cause cell death was compared to that of CN702, avector lacking the ADP gene, and Rec700, a vector containing the ADPgene.

Monolayers of LNCaP cells were infected at an MOI of one with eitherCN702, Rec700 (adp+ control), or CN751 and then seeded in 96 welldishes. Samples were harvested once a day from one day after infectionto five days after infection and scored using Promega's Cytotox 96 kit.This assay uses a coupled enzymatic reaction which converts atetrazolium salt to a red formazan product that can be determined in aplate reader at 490 nm.

Since the absorbance of a sample corresponds to the level of LDHreleased from infected cells, a plot of how a sample's absorbancechanges with time describes how efficiently the viruses studied inducecell lysis (FIG. 12). Each data point represents the average of sixteenseparate samples. The results suggest that CN751 kills cells moreefficiently than the adp− control, CN702, and similarly to the adp+control, Rec700. The concentration of LDH in the supernatant increasesrapidly from two days and reaches a maximum at four days in wellsinfected with CN751. In contrast, LDH concentration in the supernatantof CN702 infected cells begins to rise slowly at two days and continuesuntil the conclusion of the experiment. Significantly, the amount of LDHreleased from CN751 infected cells at three days is two times thatreleased from CN702 infected cells. The data demonstrate thatadenovectors with the ADP gene kill cells more efficiently thanadenovectors that lack the ADP gene.

Not only is it important for Ad vectors to kill cells efficiently, theymust also be able to shed progeny that can infect other cancer cells.Viral vectors that can shed large amounts of virus might be bettertherapeutics than those that shed only small amounts. A virus yieldassay was undertaken to evaluate whether CN751 can induce the efficientrelease of its progeny from the infected cell. A549 cells were infectedat an MOI of five. Supernatant was harvested at various times afterinfection and titered on 293 cells to determine the virus yield (FIG.13). The data suggest that cells infected with CN751 shed virus moreefficiently than those infected with CN702. At forty-eight hours postinfection, CN751 infected cells released ten times more virus than CN702infected. At seventy-two hours post infection, CN751 infected cellsreleased forty times more virus. In sum, the virus yield datademonstrate that adenovectors with the ADP gene release more virus.

In Vivo Characterization of CN751

LNCaP nude mouse xenografts were challenged with a single intratumoraldose (1×10⁴ particles/mm³ tumor) of either CN751, a vector containingthe ADP gene, or CN702, a vector lacking the gene. A third group oftumors was treated with buffer alone. The tumors were monitored weeklyfor six weeks and their relative volume was graphed against time. Theresults are shown in FIG. 14. Error bars represent the standard errorfor each sample group. The initial average tumor volume for CN751treated animals (n=14) was 320 mm³, 322 mm³ for CN702 treated (n=14),and 343 mm³ for buffer treated (n=8). The data suggest that CN751 killstumor cells more effectively than CN702. On average, tumors challengedwith CN751 remained the same size throughout the course of theexperiments while nine out of fourteen tumors (64%) regressed. Thosetreated with CN702 doubled in size. Buffer treated tumors grew to nearlyfive times their initial volume. The Students T-test indicates that thedifference in tumor size between CN751 and CN702 treated tumors wasstatistically significant from day 9 (p=0.016) through the end of theexperiment (p=0.003).

Although the foregoing invention has been described in some detail byway of illustration and example for purposes of clarity ofunderstanding, it will be apparent to those skilled in the art thatcertain changes and modifications can be practiced. Therefore, thedescription and examples should not be construed as limiting the scopeof the invention, which is delineated by the appended claims.

                   #             SEQUENCE LISTING(1) GENERAL INFORMATION:    (iii) NUMBER OF SEQUENCES: 23(2) INFORMATION FOR SEQ ID NO: 1:      (i) SEQUENCE CHARACTERISTICS:          (A) LENGTH: 822 base  #pairs           (B) TYPE: nucleic acid          (C) STRANDEDNESS: single           (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #1:GCATTGCTGT GAACTCTGTA CTTAGGACTA AACTTTGAGC AATAACACAC AT#AGATTGAG     60GATTGTTTGC TGTTAGCATA CAAACTCTGG TTCAAAGCTC CTCTTTATTG CT#TGTCTTGG    120AAAATTTGCT GTTCTTCATG GTTTCTCTTT TCACTGCTAT CTATTTTTCT CA#ACCACTCA    180CATGGCTACA ATAACTGTCT GCAAGCTTAT GATTCCCAAA TATCTATCTC TA#GCCTCAAT    240CTTGTTCCAG AAGATAAAAA GTAGTATTCA AATGCACATC AACGTCTCCA CT#TGGAGGGC    300TTAAAGACGT TTCAACATAC AAACCGGGGA GTTTTGCCTG GAATGTTTCC TA#AAATGTGT    360CCTGTAGCAC ATAGGGTCCT CTTGTTCCTT AAAATCTAAT TACTTTTAGC CC#AGTGCTCA    420TCCCACCTAT GGGGAGATGA GAGTGAAAAG GGAGCCTGAT TAATAATTAC AC#TAAGTCAA    480TAGGCATAGA GCCAGGACTG TTTGGGTAAA CTGGTCACTT TATCTTAAAC TA#AATATATC    540CAAAACTGAA CATGTACTTA GTTACTAAGT CTTTGACTTT ATCTCATTCA TA#CCACTCAG    600CTTTATCCAG GCCACTTATG AGCTCTGTGT CCTTGAACAT AAAATACAAA TA#ACCGCTAT    660GCTGTTAATT ATTGGCAAAT GTCCCATTTT CAACCTAAGG AAATACCATA AA#GTAACAGA    720TATACCAACA AAAGGTTACT AGTTAACAGG CATTGCCTGA AAAGAGTATA AA#AGAATTTC    780 AGCATGATTT TCCATATTGT GCTTCCACCA CTGCCAATAA CA    #                   # 822 (2) INFORMATION FOR SEQ ID NO: 2:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 5224 base #pairs           (B) TYPE: nucleic acid          (C) STRANDEDNESS: single           (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #2:GAATTCTTAG AAATATGGGG GTAGGGGTGG TGGTGGTAAT TCTGTTTTCA CC#CCATAGGT     60GAGATAAGCA TTGGGTTAAA TGTGCTTTCA CACACACATC ACATTTCATA AG#AATTAAGG    120AACAGACTAT GGGCTGGAGG ACTTTGAGGA TGTCTGTCTC ATAACACTTG GG#TTGTATCT    180GTTCTATGGG GCTTGTTTTA AGCTTGGCAA CTTGCAACAG GGTTCACTGA CT#TTCTCCCC    240AAGCCCAAGG TACTGTCCTC TTTTCATATC TGTTTTGGGG CCTCTGGGGC TT#GAATATCT    300GAGAAAATAT AAACATTTCA ATAATGTTCT GTGGTGAGAT GAGTATGAGA GA#TGTGTCAT    360TCATTTGTAT CAATGAATGA ATGAGGACAA TTAGTGTATA AATCCTTAGT AC#AACAATCT    420GAGGGTAGGG GTGGTACTAT TCAATTTCTA TTTATAAAGA TACTTATTTC TA#TTTATTTA    480TGCTTGTGAC AAATGTTTTG TTCGGGACCA CAGGAATCAC AAAGATGAGT CT#TTGAATTT    540AAGAAGTTAA TGGTCCAGGA ATAATTACAT AGCTTACAAA TGACTATGAT AT#ACCATCAA    600ACAAGAGGTT CCATGAGAAA ATAATCTGAA AGGTTTAATA AGTTGTCAAA GG#TGAGAGGG    660CTCTTCTCTA GCTAGAGACT AATCAGAAAT ACATTCAGGG ATAATTATTT GA#ATAGACCT    720TAAGGGTTGG GTACATTTTG TTCAAGCATT GATGGAGAAG GAGAGTGAAT AT#TTGAAAAC    780ATTTTCAACT AACCAACCAC CCAATCCAAC AAACAAAAAA TGAAAAGAAT CT#CAGAAACA    840GTGAGATAAG AGAAGGAATT TTCTCACAAC CCACACGTAT AGCTCAACTG CT#CTGAAGAA    900GTATATATCT AATATTTAAC ACTAACATCA TGCTAATAAT GATAATAATT AC#TGTCATTT    960TTTAATGTCT ATAAGTACCA GGCATTTAGA AGATATTATT CCATTTATAT AT#CAAAATAA   1020ACTTGAGGGG ATAGATCATT TTCATGATAT ATGAGAAAAA TTAAAAACAG AT#TGAATTAT   1080TTGCCTGTCA TACAGCTAAT AATTGACCAT AAGACAATTA GATTTAAATT AG#TTTTGAAT   1140CTTTCTAATA CCAAAGTTCA GTTTACTGTT CCATGTTGCT TCTGAGTGGC TT#CACAGACT   1200TATGAAAAAG TAAACGGAAT CAGAATTACA TCAATGCAAA AGCATTGCTG TG#AACTCTGT   1260ACTTAGGACT AAACTTTGAG CAATAACACA CATAGATTGA GGATTGTTTG CT#GTTAGCAT   1320ACAAACTCTG GTTCAAAGCT CCTCTTTATT GCTTGTCTTG GAAAATTTGC TG#TTCTTCAT   1380GGTTTCTCTT TTCACTGCTA TCTATTTTTC TCAACCACTC ACATGGCTAC AA#TAACTGTC   1440TGCAAGCTTA TGATTCCCAA ATATCTATCT CTAGCCTCAA TCTTGTTCCA GA#AGATAAAA   1500AGTAGTATTC AAATGCACAT CAACGTCTCC ACTTGGAGGG CTTAAAGACG TT#TCAACATA   1560CAAACCGGGG AGTTTTGCCT GGAATGTTTC CTAAAATGTG TCCTGTAGCA CA#TAGGGTCC   1620TCTTGTTCCT TAAAATCTAA TTACTTTTAG CCCAGTGCTC ATCCCACCTA TG#GGGAGATG   1680AGAGTGAAAA GGGAGCCTGA TTAATAATTA CACTAAGTCA ATAGGCATAG AG#CCAGGACT   1740GTTTGGGTAA ACTGGTCACT TTATCTTAAA CTAAATATAT CCAAAACTGA AC#ATGTACTT   1800AGTTACTAAG TCTTTGACTT TATCTCATTC ATACCACTCA GCTTTATCCA GG#CCACTTAT   1860TTGACAGTAT TATTGCGAAA ACTTCCTAAC TGGTCTCCTT ATCATAGTCT TA#TCCCCTTT   1920TGAAACAAAA GAGACAGTTT CAAAATACAA ATATGATTTT TATTAGCTCC CT#TTTGTTGT   1980CTATAATAGT CCCAGAAGGA GTTATAAACT CCATTTAAAA AGTCTTTGAG AT#GTGGCCCT   2040TGCCAACTTT GCCAGGAATT CCCAATATCT AGTATTTTCT ACTATTAAAC TT#TGTGCCTC   2100TTCAAAACTG CATTTTCTCT CATTCCCTAA GTGTGCATTG TTTTCCCTTA CC#GGTTGGTT   2160TTTCCACCAC CTTTTACATT TTCCTGGAAC ACTATACCCT CCCTCTTCAT TT#GGCCCACC   2220TCTAATTTTC TTTCAGATCT CCATGAAGAT GTTACTTCCT CCAGGAAGCC TT#ATCTGACC   2280CCTCCAAAGA TGTCATGAGT TCCTCTTTTC ATTCTACTAA TCACAGCATC CA#TCACACCA   2340TGTTGTGATT ACTGATACTA TTGTCTGTTT CTCTGATTAG GCAGTAAGCT CA#ACAAGAGC   2400TACATGGTGC CTGTCTCTTG TTGCTGATTA TTCCCATCCA AAAACAGTGC CT#GGAATGCA   2460GACTTAACAT TTTATTGAAT GAATAAATAA AACCCCATCT ATCGAGTGCT AC#TTTGTGCA   2520AGACCCGGTT CTGAGGCATT TATATTTATT GATTTATTTA ATTCTCATTT AA#CCATGAAG   2580GAGGTACTAT CACTATCCTT ATTTTATAGT TGATAAAGAT AAAGCCCAGA GA#AATGAATT   2640AACTCACCCA AAGTCATGTA GCTAAGTGAC AGGGCAAAAA TTCAAACCAG TT#CCCCAACT   2700TTACGTGATT AATACTGTGC TATACTGCCT CTCTGATCAT ATGGCATGGA AT#GCAGACAT   2760CTGCTCCGTA AGGCAGAATA TGGAAGGAGA TTGGAGGATG ACACAAAACC AG#CATAATAT   2820CAGAGGAAAA GTCCAAACAG GACCTGAACT GATAGAAAAG TTGTTACTCC TG#GTGTAGTC   2880GCATCGACAT CTTGATGAAC TGGTGGCTGA CACAACATAC ATTGGCTTGA TG#TGTACATA   2940TTATTTGTAG TTGTGTGTGT ATTTTTATAT ATATATTTGT AATATTGAAA TA#GTCATAAT   3000TTACTAAAGG CCTACCATTT GCCAGGCATT TTTACATTTG TCCCCTCTAA TC#TTTTGATG   3060AGATGATCAG ATTGGATTAC TTGGCCTTGA AGATGATATA TCTACATCTA TA#TCTATATC   3120TATATCTATA TCTATATCTA TATCTATATC TATATCTATA TATGTATATC AG#AAAAGCTG   3180AAATATGTTT TGTAAAGTTA TAAAGATTTC AGACTTTATA GAATCTGGGA TT#TGCCAAAT   3240GTAACCCCTT TCTCTACATT AAACCCATGT TGGAACAAAT ACATTTATTA TT#CATTCATC   3300AAATGTTGCT GAGTCCTGGC TATGAACCAG ACACTGTGAA AGCCTTTGGG AT#ATTTTGCC   3360CATGCTTGGG CAAGCTTATA TAGTTTGCTT CATAAAACTC TATTTCAGTT CT#TCATAACT   3420AATACTTCAT GACTATTGCT TTTCAGGTAT TCCTTCATAA CAAATACTTT GG#CTTTCATA   3480TATTTGAGTA AAGTCCCCCT TGAGGAAGAG TAGAAGAACT GCACTTTGTA AA#TACTATCC   3540TGGAATCCAA ACGGATAGAC AAGGATGGTG CTACCTCTTT CTGGAGAGTA CG#TGAGCAAG   3600GCCTGTTTTG TTAACATGTT CCTTAGGAGA CAAAACTTAG GAGAGACACG CA#TAGCAGAA   3660AATGGACAAA AACTAACAAA TGAATGGGAA TTGTACTTGA TTAGCATTGA AG#ACCTTGTT   3720TATACTATGA TAAATGTTTG TATTTGCTGG AAGTGCTACT GACGGTAAAC CC#TTTTTGTT   3780TAAATGTGTG CCCTAGTAGC TTGCAGTATG ATCTATTTTT TAAGTACTGT AC#TTAGCTTA   3840TTTAAAAATT TTATGTTTAA AATTGCATAG TGCTCTTTCA TTGAAGAAGT TT#TGAGAGAG   3900AGATAGAATT AAATTCACTT ATCTTACCAT CTAGAGAAAC CCAATGTTAA AA#CTTTGTTG   3960TCCATTATTT CTGTCTTTTA TTCAACATTT TTTTTAGAGG GTGGGAGGAA TA#CAGAGGAG   4020GTACAATGAT ACACAAATGA GAGCACTCTC CATGTATTGT TTTGTCCTGT TT#TTCAGTTA   4080ACAATATATT ATGAGCATAT TTCCATTTCA TTAAATATTC TTCCACAAAG TT#ATTTTGAT   4140GGCTGTATAT CACCCTACTT TATGAATGTA CCATATTAAT TTATTTCCTG GT#GTGGGTTA   4200TTTGATTTTA TAATCTTACC TTTAGAATAA TGAAACACCT GTGAAGCTTT AG#AAAATACT   4260GGTGCCTGGG TCTCAACTCC ACAGATTCTG ATTTAACTGG TCTGGGTTAC AG#ACTAGGCA   4320TTGGGAATTC AAAAAGTTCC CCCAGTGATT CTAATGTGTA GCCAAGATCG GG#AACCCTTG   4380TAGACAGGGA TGATAGGAGG TGAGCCACTC TTAGCATCCA TCATTTAGTA TT#AACATCAT   4440CATCTTGAGT TGCTAAGTGA ATGATGCACC TGACCCACTT TATAAAGACA CA#TGTGCAAA   4500TAAAATTATT ATAGGACTTG GTTTATTAGG GCTTGTGCTC TAAGTTTTCT AT#GTTAAGCC   4560ATACATCGCA TACTAAATAC TTTAAAATGT ACCTTATTGA CATACATATT AA#GTGAAAAG   4620TGTTTCTGAG CTAAACAATG ACAGCATAAT TATCAAGCAA TGATAATTTG AA#ATGAATTT   4680ATTATTCTGC AACTTAGGGA CAAGTCATCT CTCTGAATTT TTTGTACTTT GA#GAGTATTT   4740GTTATATTTG CAAGATGAAG AGTCTGAATT GGTCAGACAA TGTCTTGTGT GC#CTGGCATA   4800TGATAGGCAT TTAATAGTTT TAAAGAATTA ATGTATTTAG ATGAATTGCA TA#CCAAATCT   4860GCTGTCTTTT CTTTATGGCT TCATTAACTT AATTTGAGAG AAATTAATTA TT#CTGCAACT   4920TAGGGACAAG TCATGTCTTT GAATATTCTG TAGTTTGAGG AGAATATTTG TT#ATATTTGC   4980AAAATAAAAT AAGTTTGCAA GTTTTTTTTT TCTGCCCCAA AGAGCTCTGT GT#CCTTGAAC   5040ATAAAATACA AATAACCGCT ATGCTGTTAA TTATTGGCAA ATGTCCCATT TT#CAACCTAA   5100GGAAATACCA TAAAGTAACA GATATACCAA CAAAAGGTTA CTAGTTAACA GG#CATTGCCT   5160GAAAAGAGTA TAAAAGAATT TCAGCATGAT TTTCCATATT GTGCTTCCAC CA#CTGCCAAT   5220 AACA                  #                  #                   #           5224 (2) INFORMATION FOR SEQ ID NO: 3:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 19 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #3:TCGTCTTCAA GAATTCTCA              #                  #                   # 19 (2) INFORMATION FOR SEQ ID NO: 4:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 20 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #4:TTTCAGTCAC CGGTGTCGGA             #                  #                   # 20 (2) INFORMATION FOR SEQ ID NO: 5:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 20 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #5:GCATTCTCTA GACACAGGTG             #                  #                   # 20 (2) INFORMATION FOR SEQ ID NO: 6:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 20 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #6:TCCGACACCG GTGACTGAAA             #                  #                   # 20 (2) INFORMATION FOR SEQ ID NO: 7:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 21 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #7:GCCCACGGCC GCATTATATA C            #                  #                   #21 (2) INFORMATION FOR SEQ ID NO: 8:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 21 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #8:GTATATAATG CGGCCGTGGG C            #                  #                   #21 (2) INFORMATION FOR SEQ ID NO: 9:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 21 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #9:CCAGAAAATC CAGCAGGTAC C            #                  #                   #21 (2) INFORMATION FOR SEQ ID NO: 10:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #10:GTGACCGGTG CATTGCTGTG AACTCTGTA          #                  #            29 (2) INFORMATION FOR SEQ ID NO: 11:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 27 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #11:ATAAGTGGCC TGGATAAAGC TGAGTGG           #                  #             27 (2) INFORMATION FOR SEQ ID NO: 12:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 28 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #12:GTCACCGGTC TTTGTTATTG GCAGTGGT          #                  #             28 (2) INFORMATION FOR SEQ ID NO: 13:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 30 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #13:ATCCAGGCCA CTTATGAGCT CTGTGTCCTT          #                  #           30 (2) INFORMATION FOR SEQ ID NO: 14:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 26 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #14:TATCGGCCGG CATTGCTGTG AACTCT           #                  #              26 (2) INFORMATION FOR SEQ ID NO: 15:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 26 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #15:TTACGGCCGC TTTGTTATTG GCAGTG           #                  #              26 (2) INFORMATION FOR SEQ ID NO: 16:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #16:GCCTTAATTA AAAGCAAACC TCACCTCCG          #                  #            29 (2) INFORMATION FOR SEQ ID NO: 17:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 30 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #17:GTGGAACAAA AGGTGATTAA AAAATCCCAG          #                  #           30 (2) INFORMATION FOR SEQ ID NO: 18:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 30 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #18:CACCTTTTGT TCCACCGCTC TGCTTATTAC          #                  #           30 (2) INFORMATION FOR SEQ ID NO: 19:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 28 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #19:GGCTTAATTA ACTGTGAAAG GTGGGAGC          #                  #             28 (2) INFORMATION FOR SEQ ID NO: 20:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 23 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #20:GCAGCTCACT TAAGTTCATG TCG            #                  #                23 (2) INFORMATION FOR SEQ ID NO: 21:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 27 base  #pairs          (B) TYPE: nucleic acid           (C) STRANDEDNESS: single          (D) TOPOLOGY: linear    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #21:TCAGCCTAGG AAATATGACT ACGTCCG           #                  #             27 (2) INFORMATION FOR SEQ ID NO: 22:     (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 307 base #pairs           (B) TYPE: nucleic acid          (C) STRANDEDNESS: double           (D) TOPOLOGY: linear    (ix) FEATURE:           (A) NAME/KEY: CDS          (B) LOCATION: 2..304    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #22:G ATG ACC GGC TCA ACC ATC GCG CCC ACA ACG #GAC TAT CGC AAC ACC         46   Met Thr Gly Ser Thr Ile Ala Pro Thr T#hr Asp Tyr Arg Asn Thr     1               # 5                 # 10                  # 15 ACT GCT ACC GGA CTA ACA TCT GCC CTA AAT TT#A CCC CAA GTT CAT GCC       94Thr Ala Thr Gly Leu Thr Ser Ala Leu Asn Le #u Pro Gln Val His Ala                 20  #                 25  #                 30TTT GTC AAT GAC TGG GCG AGC TTG GAC ATG TG#G TGG TTT TCC ATA GCG      142Phe Val Asn Asp Trp Ala Ser Leu Asp Met Tr #p Trp Phe Ser Ile Ala             35      #             40      #             45CTT ATG TTT GTT TGC CTT ATT ATT ATG TGG CT#T ATT TGT TGC CTA AAG      190Leu Met Phe Val Cys Leu Ile Ile Met Trp Le #u Ile Cys Cys Leu Lys         50          #         55          #         60CGC AGA CGC GCC AGA CCC CCC ATC TAT AGG CC#T ATC ATT GTG CTC AAC      238Arg Arg Arg Ala Arg Pro Pro Ile Tyr Arg Pr #o Ile Ile Val Leu Asn     65              #     70              #     75CCA CAC AAT GAA AAA ATT CAT AGA TTG GAC GG#T CTG AAA CCA TGT TCT      286Pro His Asn Glu Lys Ile His Arg Leu Asp Gl #y Leu Lys Pro Cys Ser 80                  # 85                  # 90                  # 95CTT CTT TTA CAG TAT GAT TAA        #                  #                 307 Leu Leu Leu Gln Tyr Asp                 100(2) INFORMATION FOR SEQ ID NO: 23:      (i) SEQUENCE CHARACTERISTICS:          (A) LENGTH: 101 amino  #acids           (B) TYPE: amino acid          (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:  #23:Met Thr Gly Ser Thr Ile Ala Pro Thr Thr As #p Tyr Arg Asn Thr Thr  1               5  #                 10  #                 15Ala Thr Gly Leu Thr Ser Ala Leu Asn Leu Pr #o Gln Val His Ala Phe             20      #             25      #             30Val Asn Asp Trp Ala Ser Leu Asp Met Trp Tr #p Phe Ser Ile Ala Leu         35          #         40          #         45Met Phe Val Cys Leu Ile Ile Met Trp Leu Il #e Cys Cys Leu Lys Arg     50              #     55              #     60Arg Arg Ala Arg Pro Pro Ile Tyr Arg Pro Il #e Ile Val Leu Asn Pro 65                  # 70                  # 75                  # 80His Asn Glu Lys Ile His Arg Leu Asp Gly Le #u Lys Pro Cys Ser Leu                 85  #                 90  #                 95Leu Leu Gln Tyr Asp             100

What is claimed is:
 1. A replication-competent adenovirus vectorcomprising two adenoviral genes essential for replication undertranscriptional control of the same α-fetoprotein transcriptionalregulatory element (AFP-TRE).
 2. The adenovirus vector of claim 1,wherein the adenovirus genes essential for replication are selected fromthe group consisting of E1A, E1B and E4.
 3. The adenovirus vector ofclaim 1, wherein the AFP-TRE comprises an enhancer from an AFP gene. 4.The adenovirus vector of claim 1, wherein the AFP-TRE comprises apromoter from a AFP gene.
 5. The adenovirus vector of claim 1, whereinthe AFP-TRE comprises an AFP promoter and an AFP enhancer.
 6. A methodof propagating adenovirus, specific for cells which allow an AFP-TRE tofunction, said method comprising combining an adenovirus according toclaim 1 with cells which allow an AFP-TRE to function, whereby saidadenovirus is propagated.
 7. The adenovirus vector of claim 1, furthercomprising a third adenoviral gene under transcriptional control of acell-specific TRE.
 8. A composition comprising an adenovirus of claim 1and a pharmaceutically acceptable excipient.
 9. A host cell comprisingthe adenoviral vector of claim
 1. 10. The adenovirus vector of claim 9,wherein the adenovirus genes are E1A and E1B.
 11. The adenovirus vectorof claim 3, wherein the enhancer comprises nucleotides from about 1 toabout 300 of SEQ ID NO:
 1. 12. The adenovirus vector of claim 3, whereinthe AFP-TRE comprises nucleotides from about 300 to about 600 of SEQ IDNO:
 1. 13. The adenovirus vector of claim 3, wherein the AFP-TREcomprises nucleotides from about 1 to about 600 of SEQ ID NO:
 1. 14. Theadenovirus vector of claim 4, wherein the AFP-TRE comprises nucleotidesfrom about 600 to about 827 of SEQ ID NO:
 1. 15. The adenovirus vectorof claim 5, wherein the AFP-TRE comprises SEQ ID NO:
 1. 16. Theadenovirus vector of claim 5, wherein the AFP-TRE comprises SEQ ID NO:2.
 17. The adenoviral vector of claim 7, wherein the cell-specific TREis prostate-cell specific.
 18. The adenoviral vector of claim 7, whereinthe cell-specific TRE is an AFP-TRE.
 19. A host cell comprising theadenoviral vector of claim
 7. 20. A composition comprising an adenovirusof claim 7 and a pharmaceutically acceptable excipient.
 21. A method ofpropagating adenovirus, specific for cells which allow an AFP-TRE tofunction, said method comprising combining an adenovirus according toclaim 7 with cells which allow an AFP-TRE to function, whereby saidadenovirus is propagated.
 22. The adenoviral vector of claim 17, whereinthe prostate-cell specific TRE is derived from the prostate specificantigen gene, the human kallikrien gene, or the probasin gene.